LICENSURE PROFESSIONAL EXPERIENCEweb-prod-2.pharm.uic.edu/webdav/rdidom1/pci/cv-Rob... · 2019-04-15 · Practice and Research Network outlining recommendations for training of cardiovascular

ROBERT J. DIDOMENICO, JR. CURRICULUM VITAE

PERSONAL DATA University of Illinois at Chicago College of Pharmacy Department of Pharmacy Practice (M/C 886) 833 South Wood Street Chicago, Illinois 60612 Phone: (312) 996-1342 Fax: (312) 996-0379 Email: [email protected] Website: https://pharmacy.uic.edu/people-resources/directory/rdidom1 LICENSURE Registered Pharmacist, Illinois, Lic. No. 051-040893 PROFESSIONAL EXPERIENCE 1997 – 1999 Pharmacotherapist, Amiodarone/Electrophysiology Clinic University of Illinois Medical Center at Chicago Heart Center

1997 – 1999 Specialist in Poison Information Illinois Poison Control Center Metropolitan Chicago Healthcare Council Rush-Presbyterian-St. Lukes Medical Center

1998 – 1999 Clinical Pharmacist, Cardiology Clinic Veterans Administration Chicago Healthcare System West Side Division

1999 – present Cardiovascular Clinical Pharmacist University of Illinois Hospital & Health Sciences System Department of Hospital Pharmacy Services

ACADEMIC APPOINTMENTS University of Illinois at Chicago

1996 – 1999 Clinical Associate College of Pharmacy Department of Pharmacy Practice

1999 – 2006 Clinical Assistant Professor College of Pharmacy Department of Pharmacy Practice

2003 – 2008 Team Leader, Critical Care Pharmacotherapy University of Illinois Medical Center at Chicago Department of Hospital Pharmacy Services College of Pharmacy Department of Pharmacy Practice

2003 – present Center Affiliate Center for Pharmacoepidemiology and Pharmacoeconomic Research (CPR) College of Pharmacy

2004 – 2005 Clinical Assistant Professor

Robert J. DiDomenico, Jr., PharmD, BCPS-AQ Cardiology, FCCP, FHFSA, FACC

Curriculum Vitae

Page 2

College of Medicine Section of Cardiology

2006 – 2015 Clinical Associate Professor College of Pharmacy Department of Pharmacy Practice

2007 – 2017 Curricular Team Leader College of Pharmacy Classes: 2010, 2013, 2014 – 2017 (3rd professional year)

2015 – 2017 Clinical Professor College of Pharmacy Department of Pharmacy Practice

Percent effort Patient care and Clinical Teaching 46% Public and Professional Service 28% Administration 8% Research and Scholarship 7% Didactic teaching 6% Mentoring 5%

2017 – present Associate Professor with tenure College of Pharmacy Department of Pharmacy Practice

Percent effort Research and Scholarship 25% Patient care and Clinical Teaching 25% Public and Professional Service 25% Administration 10% Didactic teaching 10% Mentoring 5%

POST-DOCTORAL TRAINING 1996 – 1997 Pharmacy Practice Residency Director: Linda R. Bressler, Pharm.D. University of Illinois at Chicago College of Pharmacy

1997 – 1999 Cardiovascular Pharmacotherapy Fellowship Director: Jerry L. Bauman, Pharm.D., BCPS, FCCP, FACC University of Illinois at Chicago College of Pharmacy

EDUCATION 1989 – 1992 Pre-Pharmacy Studies University of Illinois at Chicago

1992 – 1996 Doctor of Pharmacy (with Honors) University of Illinois at Chicago College of Pharmacy

CERTIFICATION 1996 – present CPR Healthcare Provider. American Heart Association. 1996 – present Acute Cardiac Life Support Provider. American Heart Association. 2015 – present Added Qualifications in Cardiology (AQ Cardiology). Board of Pharmaceutical Specialties.


Curriculum Vitae

Page 3

2015 – present Board Certified Pharmacotherapy Specialist (BCPS). Board of Pharmaceutical Specialties HONORS AND AWARDS 1997 Richard A. Hutchinson Award for Excellence in Pharmacy Practice 1998 ACCP 1998 Spring Practice and Research Forum Best Student, Resident, Fellow

Paper Award Competition Finalist 1999 Academic Employee of the Month, University of Illinois Hospital 1999 Marion Merrell Dow Fellowship Research Award 2001 Inducted into Rho Chi Society, Phi Chapter 2002 Class Act Award, Employee Recognition Committee, University of Illinois

Hospital 2005 Preceptor of the Year; University of Illinois at Chicago, College of Pharmacy,

Pharmacy Practice Residency 2005 PharmD of the Year Nominee; University of Illinois at Chicago, College of

Medicine Housestaff Physicians 2005 Teacher of the Year Honorable Mention; University of Illinois at Chicago, College

of Pharmacy, Class of 2007 2006 Preceptor of the Year; University of Illinois at Chicago, College of Pharmacy,

Class of 2006 2006 PharmD of the Year Nominee; University of Illinois at Chicago, College of

Medicine Housestaff Physicians 2007 12th ISPOR Annual International Meeting Contributed Research Award for Best

Poster Presentation 2007 PharmD of the Year Nominee; University of Illinois at Chicago, College of

Medicine Housestaff Physicians 2008 American College of Clinical Pharmacy (ACCP) Research Institute Investigator

Development Award 2008 Preceptor of the Year; University of Illinois at Chicago, College of Pharmacy,

Pharmacy Practice (PGY1) Residency 2008 Golden Apple Award Nominee; University of Illinois at Chicago, College of

Pharmacy, Class of 2008 2008 Preceptor of the Year Nominee; University of Illinois at Chicago, College of

Pharmacy, Class of 2008 2012 Inducted into Phi Lambda Sigma Pharmacy Leadership Society, Alpha lota

chapter 2013 Fellow, American College of Clinical Pharmacy (FCCP) 2017 Fellow, American College of Cardiology (FACC) 2017 Fellow, Heart Failure Society of America (FHFSA) LEADERSHIP ACTIVITIES Organizational

American College of Clinical Pharmacy (ACCP) Practice-Based Research Network (PBRN) 2016 – 2017 Vice-Chair, Community Advisory Panel (CAP) 2017 – 2018 Chair, Community Advisory Panel (CAP)

American College of Clinical Pharmacy (ACCP) Cardiology Practice and Research Network (PRN) 2002, 2008 Chair-Elect Candidate 2010 – 2012 Co-Chair, Awards and Recognition Committee 2014 – 2015 Chair, Research and Scholarship Committee


Curriculum Vitae

Page 4

2015 – 2016 Chair-Elect 2015 – 2016 Vice-Chair, Programming Committee 2016 – 2017 Chair 2016 – 2017 Chair, Programming Committee 2017 – 2018 Chair, Nominations Committee

University of Illinois Hospital & Health Sciences Center 2008 – 2010 Co-Chair, Cardiovascular (CV) Quality Improvement (QI) Committee 2009 – 2010 Chair, CVQI Committee, 30-day Readmissions Subcommittee 2016 – 2017 Chair, PATient Navigator to rEduce Readmissions (PArTNER) Publications

Committee

University of Illinois at Chicago College of Pharmacy 2005 – 2006 Chair, EPC Pharmacokinetics Working Group 2008 – 2018 Chair, Educational Policy Committee (EPC) Significant achievements under my leadership include incorporation

of lecture capture technology into the classroom, expansion to a distance campus (Rockford, IL; 2010), ACPE re-accreditation (2014-5), revised professional curriculum (2015), implementation of revised curriculum (2016-2018)

2013 – 2014 Co-Chair, American Council for Pharmaceutical Education (ACPE) Self-Study Committee, Curriculum Subcommittee

2014 – 2015 Chair, Curriculum Revision Phase III-Curriculum Development

University of Illinois at Chicago College of Pharmacy Department of Pharmacy Practice 2005 Chair, Strategic Planning Committee, Workload Subcommittee

2005 Chair, Strategic Planning Committee, Curriculum Revision Subcommittee

2007 Chair, Drug Information Group Director Search Committee

2018 – present Chair, Promotion and Tenure Committee

2019 – present Interim Assistant Head

Pharmaceutical Industry 2005 Co-Chair, Scios, Inc. Regional Pharmacy Advisory Board; Chicago, Illinois

Community 2017 – 2018 Lead, Residential Promotion. St. Alphonsus/St. Patrick School Celtic Fund

Marketing Committee. Lemont, Illinois.

PUBLICATIONS (Corresponding author underlined) Scholarly Works in Progress 1. Goncharenko A, Groo VL, Mansour I, Gans C, Stamos T, DiDomenico RJ. Trends in medication

optimization during hospitalization for acute decompensated heart failure. J Card Fail [In preparation].

2. DiDomenico RJ, Ng T, Benge CD, Hale G, Nappi J, Pickworth K, Campbell KB, Buckley L, Macaulay TE, Short, M, Ripley TL. Comparison of PGY2 cardiology pharmacy residency learning experiences. Am J Health-Syst Pharm [In preparation].

3. Patel H, Calip GS, DiDomenico RJ, Schumock G, Suda K, Lee TA. Prevalence of cardiac risk factors in patients using azithromycin before and after the FDA warning. [In preparation].


Curriculum Vitae

Page 5

4. Landup D, Bress AP, DiDomenico RJ. Chapter 5: Ischemic heart disease. In: Katz M, Matthias K, Chisholm-Burns MA, eds. Pharmacotherapy Principles & Practice Study Guide: A Case Based Care Plan Approach, 5th edition. Chicago: McGraw-Hill. [In preparation].

5. Hellenbart EL, Dwyer SM, DiDomenico RJ. Chapter 7: Principles of heart failure pharmacotherapy. In Butler J, Skopicki H, Murali S, Kalogeropoulos A, eds. Heart Failure: An Essential Clinical Guide. New York: Taylor & Francis. [in preparation].

6. DiDomenico RJ, Dobesh PP, Finks SW. Chapter 33: Acute coronary syndromes. In DiPiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod V, eds. Pharmacotherapy: A Pathophysiologic Approach, 11th ed. New York: McGraw-Hill Education. [Submitted].

7. Ng T, DiDomenico RJ, Ripley TL, Benge CD, Buckley L, Campbell KB, Hale G, Macaulay TE, Nappi J, Pickworth K, Short, M,. An opinion paper of the American College of Clinical Pharmacy Cardiology Practice and Research Network outlining recommendations for training of cardiovascular pharmacy specialists in post-graduate year 2 residency programs. JACCP [Submitted].

8. Basu S, Bracken N, Dickens C, DiDomenico RJ, Gallardo R, Gordeuk V, Hsu L, Illendula S, Joo M, Mutso A, Pickard AS, Pittendrigh B, Prieto-Centurion V, Williams M, Krishnan JA. Design of the Patient Navigator to Reduce Readmissions (PArTNER) study: a pragmatic clinical effectiveness trial. Contemp Clin Trials Commun [Submitted].

9. Kim K, Ardati A, Cavallari L, Touchette DR, DiDomenico RJ. Cost-effectiveness of genotype/phenotype driven ticagrelor versus clopidogrel selection in patients with acute coronary syndrome. Cardiovasc Drug Ther [Submitted].

Primary Literature 1. DiDomenico RJ, Chami YG, Bauman JL. Unstable Angina Pectoris Associated with Phentermine in

a Patient with Known Coronary Artery Disease. J Appl Ther Res 1998;2:63-7.

2. DiDomenico, RJ. New antithrombotics for the ICU setting: GP IIb/IIIa inhibitors, low-molecular-weight heparins, and direct thrombin inhibitors. Crit Care Nurs Q 2000;22(4):61-74. PMID: 11852966. Invited review.

3. DiDomenico RJ, Sanoski CA, Walton SM, Bauman JL. Analysis of the use of digoxin immune Fab for the treatment of non-life-threatening digoxin toxicity. J Cardiovasc Pharmacol Therapeut 2000;5(2):77-85. PMID: 11150387

4. Schoen MD, DiDomenico RJ, Connor SE, Bauman JL. Impact of the cost of prescription drugs on clinical outcomes in indigent patients with heart disease. Pharmacotherapy 2001;21:1455-63. PMID: 11765297

5. DiDomenico RJ. Reimbursement mechanisms for glycoprotein IIb/IIIa-receptor inhibitors. Am J Health-Syst Pharm 2002;59(Suppl 7):S37-42. Invited review. PMID: 12434713

6. Galanter WL, DiDomenico RJ, Polikaitis A. Preventing exacerbation of an ADE with automated decision support. J Healthc Inf Manag 2002;16:44-9. PMID: 12365299

7. Bauman JL, DiDomenico RJ. Cocaine-induced channelopathies: emerging evidence on the multiple mechanisms of sudden death. J Cardiovasc Pharmacol Therapeut 2002;7:195-202. PMID: 12232568. Invited review.

8. DiDomenico RJ, Eyrich HM. Did contrast nephropathy in RAPPID really occur? J Am Coll Cardiol 2003;42:2167. [letter]. PMID: 14680745

9. Eckhoff C, DiDomenico RJ, Shapiro NL. Initiating warfarin therapy: is 5mg or 10mg superior? Ann Pharmacother 2004;38:2115-21. Epub 2004 Nov. 2. PMID: 15522981

10. Galanter WL, Polikaitis A, DiDomenico RJ. A trial of automated safety alerts for inpatient digoxin use with computerized physician order entry. J Am Med Inform Assoc 2004;11:270-7. Epub 2004 Apr 2. PMID: 15064288


Curriculum Vitae

Page 6

11. DiDomenico RJ, Park H, Southworth MR, Eyrich HM, Lewis RK, Finley JM, Schumock GT. Guidelines for acute decompensated heart failure treatment. Ann Pharmacother 2004;38:649-60. Epub 2004 Feb 24. ACPE Program # 407-000-04-015-H01. PMID: 14982975

12. DiDomenico RJ. Randomized trial of warfarin nomograms. Ann Intern Med 2004;140:489-90. [letter]. PMID: 15023723

13. DiDomenico RJ, Massad MG, Kpodonu J, Navarro RA, Geha A. Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass. Chest 2005;127:1828-35. PMID: 15888865

14. Galanter WL, DiDomenico RJ, Polikaitis A. A trial of automated decision support alerts for contraindicated medications using computerized physician order entry. J Am Med Inforn Assoc 2005;12:269-74. Epub 2005 Jan. 31. PMID: 15684124

15. DiDomenico RJ, Massad MG. Pharmacologic strategies to prevent atrial fibrillation after open-heart surgery. Ann Thorac Surg 2005;79:728-40. PMID: 15680883

16. Desai SS, Massad MG, DiDomenico RJ, Abdelhady K, Hanhan Z, Lele H, Snow NJ, Geha AS. Recent developments in antithrombotic therapy: will sodium warfarin be a drug of the past? Rec Patents Cardiovasc Drug Disc 2006;1:307-16. PMID: 18221095

17. Bauman JL, DiDomenico RJ, Viana M, Fitch M. A method of determining the dose of digoxin for heart failure in the modern era. Arch Intern Med 2006;166:2539-45. PMID: 17159022

18. Bauman JL, DiDomenico RJ, Galanter WL. Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs 2006;6:77-86. PMID: 16555861. Invited review.

19. Vats V, DiDomenico RJ, Wojtynek J, Theobald J, Schumock GT. Hospital policies for treatment of acute decompensated heart failure. Ann Pharmacother 2007;41:562-7. Epub 2007 Mar. 20. PMID: 17374618

20. DiDomenico RJ, Perez A, Eyrich HM, Fontana DR, Kondos GT, Schumock GT. Impact of treatment guidelines on clinical and economic outcomes of acute decompensated heart failure. Ann Pharmacother 2008;42:327-33. Epub 2008 Feb. 26. doi: 10.1345/APH.1k496.

21. DiDomenico RJ, Kondos GT, Dickens C. Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail 2010;3:e13.[letter]. doi: 10.1161/CIRCHEARTFAILURE.110.947614.

22. Chow SL, Singh H, DiDomenico RJ, Dunn SP, Johnson SG, Marrs JC, Vardeny O, Bleske BE. Key articles related to complementary and alternative medicine in cardiovascular disease: Part 2. Pharmacotherapy 2011;31:208e-277e. doi: 10.1592/phco.31.10.1041.

23. Perez A, Touchette DR, DiDomenico RJ, Stamos TD, Walton SM. Comparison of rate control versus rhythm control for management of atrial fibrillation in patients with coexisting heart failure: a cost-effectiveness analysis. Pharmacotherapy 2011;31:552-65. doi: 10.1592/phco.31.6.552.

24. Yu S, Galanter WL, DiDomenico RJ, Borkowsky S, Schiff GD, Lambert BL. Selection of drug-laboratory result pairs for an inpatient asynchronous alert program: results of a Delphi survey. Am J Health-Syst Pharm 2011;68:407-14. doi: 10.2146/ajhp100215.

25. Milfred-Laforest SK, Chow SL, DiDomenico RJ, Dracup K, Ensor C, Gattis-Stough W, Heywood JT, Lindenfeld J, Page II RL, Patterson JH, Vardeny O, Massie BM. Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network. J Cardiac Fail 2013;19:354-60. Epub 2013 Apr 6. doi: 10.1016/j.cardfail.2013.02.002.

26. Milfred-Laforest SK, Chow SL, DiDomenico RJ, Dracup K, Ensor C, Gattis-Stough W, Heywood JT, Lindenfeld J, Page II RL, Patterson JH, Vardeny O, Massie BM. Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network. Pharmacotherapy 2013;33:529-48. Epub 2013 May 3. doi: 10.1002/phar.1295.


Curriculum Vitae

Page 7

27. Wiggins BS, Rodgers JE, DiDomenico RJ, Miller AE, Page RL. Discharge counseling for patients with heart failure or myocardial infarction: a best practices model developed by the members of the American College of Clinical Pharmacy’s Cardiology PRN based on the Hospital to Home (H2H) Initiative. Pharmacotherapy 2013;33:558-80. Epub 2013 Mar 25. doi: 10.1002/phar.1231.

28. Nutescu EA, Bathija S, Chan J, Engle J, Grim S, Mucksavage J, Ohler K, Shapiro NL, Tesoro E, DiDomenico RJ. Balance of Academic Responsibilities of Clinical Track Pharmacy Faculty. Pharmacotherapy 2014;34:1239-49. Epub 2014 Dec 4. doi: 10.1002/phar.1521.

29. DiDomenico RJ, Bress AP, Na-Thalang K, Tsao YY, Groo VL, Deyo KL, Patel SR, Bishop JR, Bauman JL. Use of a Simplified Nomogram to Individualize Digoxin Dosing versus Standard Dosing in Patients with Heart Failure. Pharmacotherapy 2014;34:1121-31. Epub 2014 Aug 28. doi: 10.1002/phar.1480.

30. Dorsch MP, Lose J, DiDomenico RJ. The effect of cardiovascular credentialed pharmacists on process measures and outcomes in myocardial infarction and heart failure. Pharmacotherapy 2014;34:803-8. Epub 2014 Jun 5. doi: 10.1002/phar.1444.

31. Prieto-Centurion V, Markos MA, Ramey NI, Gussin H, Nyenhuis S, Joo MJ, Prasad, B, Bracken N, DiDomenico R, Godwin PO, Jaffe HA, Kalhan, R, Pickard AS, Pittendrigh B, Schatz B, Sullivan JL, Thomashow BM, Williams MV, Krishnan JA. Interventions to reduce rehospitalizations after chronic obstructive pulmonary disease exacerbations: a systematic review. Ann Am Thorac Soc 2014;11:417-24. doi: 10.1513/Annals/ATS.201308-254OC.

32. Lose J, Dorsch MP, DiDomenico RJ. Comparison of practice patterns between inpatient cardiology pharmacists with and without added qualifications in cardiology. Hosp Pharm 2015;50:51-8. doi: 10.1310/hjp5001-051.

33. Ursan ID, Krishnan JA, Pickard AS, Calhoun E, DiDomenico R, Prieto-Centurion V, Sullivan JL, Valentino L, Williams MV, Joo M. Engaging patients and caregivers to design transitional care management services at a minority serving institution. J Health Care Poor Underserved 2016;27:352-65. doi: 10.1353/hpu.2016.0026.

34. Hanigan S, DiDomenico RJ. Emerging therapies for acute and chronic heart failure: hope or hype? J Pharm Pract 2016;29:35-45. doi: 10.1177/1933719115615877. Invited review.

35. DiDomenico RJ. Digoxin remains a viable option to control heart rate in patients with atrial fibrillation. Can J Hosp Pharm 2017;70:391-2. doi: http://dx.doi.org/10.4212/cjhp.v70i5.1701. Invited review.

36. Haines ST, Baker WL, DiDomenico RJ. Improving Peer Review: What Journals Can Do. Am J Health-Syst Pharm 2017;74:2086-9. Epub 2017 Oct 26. doi: 10.2146/ajhp170188. Invited review.

37. DiDomenico RJ, Baker WL, Haines ST. Improving Peer Review: What Reviewers Can Do. Am J Health-Syst Pharm 2017;74:2080-4. Epub 2017 Oct 26. doi: 10.2146/ajhp170190. Invited review.

38. Baker WL, DiDomenico RJ, Haines ST. Improving Peer Review: What Authors Can Do. Am J Health-Syst Pharm 2017;74:2076-9. Epub 2017 Oct 26. doi: 10.2146/ajhp170187. Invited review.

39. Allender JE, Reed BN, Foster JL, Moretz JD, Oliphant CS, Jennings DL, DiDomenico RJ, Coons JC. Pharmacologic considerations in patients receiving left ventricular percutaneous mechanical circulatory support. Pharmacotherapy 2017;37:1272-83. Epub 2017 Jul 25. doi: 10.1002/phar.1995.

40. Kim K, Lee TA, Ardati AK, DiDomenico RJ, Touchette DR, Walton SM. Comparative effectiveness of oral antiplatelet agents in patients with acute coronary syndrome. Pharmacotherapy 2017;37:877-87. Epub 2017 May 27. doi: 10.1002/phar.1961

41. Kim K, DiDomenico RJ, Touchette DR, Walton SM. Letter—The authors respond. J Manag Care Spec Pharm 2017;23:599-600. doi: 10.18553/jmcp.2017.23.5.599

42. Kim K, Lee TA, Touchette DR, DiDomenico RJ, Ardati AK, Walton SM. Contemporary trends in oral antiplatelet agent use in patients treated with percutaneous coronary intervention for acute coronary syndrome. J Manag Care Spec Pharm 2017;23:57-63. doi: 10.18553/jmcp.2017.23.1.57.


Curriculum Vitae

Page 8

43. Kim, K, Lee TA, DiDomenico RJ, Ardati AK, Touchette DR, Walton SM. Comparison of six-month costs between oral antiplatelet agents following acute coronary syndrome. J Manag Care Spec Pharm 2018;24:800-12. doi: 10.18552/jmcp.2018.24.8.800.

44. DiDomenico RJ. Residency application deadlines: Can we all just agree on a date? Am J Health-Syst Pharm 2018;75:849-50. doi: 10.2146/ajhp170882.

45. Zueger PM, Kumar VM, Harrington R, Rigoni G, Atwood AM, DiDomenico RJ, Touchette DR. Cost-effectiveness analysis of sacubitril-valsartan for the treatment of heart failure with reduced ejection fraction in the United States. Pharmacotherapy 2018;38:520-30. Epub 2018 Mar 30. doi: 10.1002/phar.2108.

46. DiDomenico RJ. Cardiology clinical pharmacy practice—keep spreading the news! JACCP 2018. Epub 2018 Oct 23. https://doi.org/10.1002/jac5.1048. Invited editorial.

47. Gasbarro NM, DiDomenico RJ. Frequency of “on-label” use of intravenous diltiazem for rate control in patients with acute-onset atrial fibrillation or atrial flutter. Am J Health-Syst Pharm 2019;76:214-20. https://doi.org/10.1093/ajhp/zxy033

48. Reed BN, DiDomenico RJ, Allender JE, Coons JC, Cox JF, Johnson D, Oliphant CS, Jennings DL. Survey of anticoagulation practices with the Impella percutaneous ventricular assist device at high-volume centers. J Interv Cardiol 2019;3791307. https://doi.org/10.1155/2019/3791307

Book Chapters 1. DiDomenico RJ, Einhorn AE. Medical emergencies: cardiac arrest. In: Anderson PO, Knoben JE,

Troutman WG, eds. Handbook of Clinical Drug Data, 10th ed. Chicago: McGraw-Hill, 2002.

2. DiDomenico RJ. Cardiovascular drugs: inotropic drugs. In: Anderson PO, Knoben JE, Troutman WG, eds. Handbook of Clinical Drug Data, 10th ed. Chicago: McGraw-Hill, 2002.

• 11th edition, 2010.

3. DiDomenico RJ. Cardiovascular drugs: nitrates. In: Anderson PO, Knoben JE, Troutman WG, eds. Handbook of Clinical Drug Data, 10th ed. Chicago: McGraw-Hill, 2002.

• 11th edition, 2010.

4. DiDomenico RJ. Hematologic drugs: coagulants & anticoagulants. In: Anderson PO, Knoben JE, Troutman WG, eds. Handbook of Clinical Drug Data, 10th ed. Chicago: McGraw-Hill, 2002.

5. DiDomenico RJ. Hematologic drugs: hematopoietics. In: Anderson PO, Knoben JE, Troutman WG, eds. Handbook of Clinical Drug Data, 10th ed. Chicago: McGraw-Hill, 2002.

6. DiDomenico RJ, Mucksavage J. Anemia of critical illness: prevention and treatment. In: Pharmacotherapy Self-Assessment Program, 5th ed; Book 11: Critical Care/Transplantation. Kansas City: American College of Clinical Pharmacy, 2006.

7. Cavallari LH, DiDomenico RJ. Chapter 4: Ischemic heart disease. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, Dipiro JT, eds. Pharmacotherapy Principles & Practice. Chicago: McGraw-Hill, 2007. Book received the American Medical Writers Association Distinguished 2008 Medical Book Healthcare Professionals Award.

• 2nd edition, 2010. • 3rd edition, 2013. • 4th edition (DiDomenico RJ, Cavallari LH), 2016.

https://ppp.mhmedical.com/content.aspx?bookid=1793&sectionid=120648222 • 5th edition (Landup D, DiDomenico RJ), 2019.

https://ppp.mhmedical.com/content.aspx?bookid=2440&sectionid=189491747

8. Cavallari LH, DiDomenico RJ, Peska G. Chapter 5: Ischemic heart disease. In: Katz M, Matthias K, Chisholm-Burns MA, eds. Pharmacotherapy Principles & Practice Study Guide: A Case Based Care Plan Approach. Chicago: McGraw-Hill, 2010.

• 3rd edition (Cavallari LH, DiDomenico RJ, Bress A), 2013. • 4th edition (Bress A, Cavallari LH, DiDomenico RJ), 2017.


Curriculum Vitae

Page 9

9. DiDomenico RJ, Cavallari LH. Chapter 6: Chronic stable angina. In: Crouch MA, ed. Cardiovascular Pharmacotherapy: A Point of Care Guide. Bethesda: American Society of Health-System Pharmacists, 2010.

10. DiDomenico RJ. Chapter 6. Fibrinolytics. In: Wiggins B, Sanoski S, eds. Emergency Cardiovascular Pharmacotherapy: A Point-of-Care Guide. Bethesda: American Society of Health-System Pharmacists, 2012.

11. DiDomenico RJ, Page RL. Chapter 12: Digoxin. In Murphy J, ed. Clinical Pharmacokinetics, 6th ed. Bethesda: American Society of Health-System Pharmacists, 2017.

12. Dobesh PP, DiDomenico RJ, Rogers KC. Chapter 32: Stable ischemic heart disease. In DiPiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod V, eds. Pharmacotherapy: A Pathophysiologic Approach, 11th ed. New York: McGraw-Hill Education, 2019. https://accesspharmacy.mhmedical.com/content.aspx?bookid=2577&sectionid=211042403

Miscellaneous Projects/Publications (Non-Peer Reviewed) 1. DiDomenico RJ, Seeger JD. Clinically relevant drug-drug interactions with warfarin (CoumadinÒ).

UICMC Hospital Pharmacy Services and Drug Information Service; Chicago, Illinois. Nursing-Rx News 1997;3(6).

2. DiDomenico RJ. Continuing education: review of the glycoprotein IIb/IIIa inhibitors. KeePosted 1998;23(9):6-16.

3. DiDomenico RJ, Schoen MD. Clinical case study: management of hypertension. KeePosted 1998;23(5):6-12.

4. DiDomenico RJ. Ischemic heart disease. CPE Program: Pharmaceutical Care and Disease State Management in Community Pharmacy. June, 2000.

5. DiDomenico RJ. Therapeutic class review of thrombolytic agents for myocardial infarction. Novation/University Health-System Consortium. March, 2000.

6. DiDomenico RJ. Clinical use of fenoldopam, a selective dopamine agonist: potential application to the perioperative Setting. Anesthesia Today 2002;13:19-26.

7. DiDomenico RJ. What’s new…in the management of hypertension and dyslipidemia? Presented as part of a pharmacy distance learning program for Continuing Education credit (ACPE Universal Program #: 073-000-03-082-L01) entitled “A Review of Selected New Drugs During the Beginning of the Twenty-First Century sponsored by University of Wisconsin-Madison School of Pharmacy, Department of Extension Services in Pharmacy (ESP). September 23 – November 11, 2003.

8. Beitelshees AL, Humma, LM, DiDomenico RJ. Low-molecular-weight heparin vs unfractionated heparin in acute coronary syndromes: Which should be used in patients going to the cath lab? Today in Cardiology 2003;6(1):18.

9. DiDomenico RJ. Coronary artery disease. Tech Topics™ July 2004;9(3):1-28. ACPE Program # 121-000-03-109-H01.

10. DiDomenico RJ. Drug therapy to prevent atrial fibrillation after open heart surgery in patients at risk. Anesthesia Today 2005;16:21-6.

11. Fontana D, DiDomenico RJ. Nesiritide: the latest drug for treating acutely decompensated congestive heart failure. Fremont: Scios, Inc., 2006.

12. DiDomenico RJ. Using critical pathways and pharmacoeconomics to guide ADHF treatment decisions. Continuing education credit: 0.2 CEU (ACPE Program #204-000-06-407-H01). Bethesda: ASHP Advantage, 2006.

13. DiDomenico RJ. Pharmacological management of AF. Hospital Pharmacy Europe 2006;May/June:1-2.


Curriculum Vitae

Page 10

14. Crouch MA, DiDomenico RJ, Rodgers JE. Applying consensus guidelines in the management of acute decompensated heart failure. Continuing education credit: 0.2 CEU (ACPE Program #204-000-06-407-H01). Bethesda: ASHP Advantage, 2007.

15. Labinov Y, DiDomenico R. The role of platelet function monitoring during thienopyridine/P2Y12 therapy. Cardiology Today, March 2013.

16. Labinov Y, DiDomenico R, Cavallari L. Pharmacists’ role in warfarin pharmacogenetics. KeePosted 2013;39:9-10.

17. Gasbarro N, DiDomenico RJ. The role of ivabradine in reducing the risk for cardiovascular mortality or hospitalization for worsening heart failure. Pharmacy Practice News Special Report/Advertorial. New York: McMahon Publishing. May, 2016.

18. DiDomenico R. Message from the chair: righting a wrong on board certification. The Heart Beat: Cardiology Practice and Research Network (PRN) Newsletter. Lanexa: American College of Clinical Pharmacy. July, 2017.

19. Baker WL, DiDomenico RJ. Heart failure: pumping up knowledge, circulating new approaches. Drug Topics;May 2017:54-64. Continuing education credit: 0.2 CEU (ACPE Program #0009-9999-17-008-H01-P, #0009-9999-17-008-H01-T).

20. DiDomenico R. Message from the chair. Cardiology Practice and Research Network (PRN) Membership Information. Lanexa: American College of Clinical Pharmacy. Spring, 2017.

SCIENTIFIC ABSTRACTS (Presenting author italicized) Published Abstracts

1. DiDomenico RJ, Sanoski CA, Walton SM, Bauman JL. Cost-Effectiveness Analysis of the Use of Digoxin Immune Fab for the Treatment of Non-Life-Threatening Digoxin Toxicity. Pharmacotherapy 1998;18:427[Abstract 8]. Poster presentation: American College of Clinical Pharmacy (ACCP) 1998 Spring Practice and Research Forum; Palm Springs, CA. April, 1998.

2. DiDomenico RJ, Schoen MD, Connor SE, Bauman JL. Impact of Cost of Prescription Drugs on Clinical Outcomes in Patients with Heart Disease. Pharmacotherapy 1999;19:506[Abstract 181]. Platform presentation: American College of Clinical Pharmacy (ACCP)/European Society of Clinical Pharmacy (ESCP) International Congress on Clinical Pharmacy; Orlando, FL. April, 1999.

3. DiDomenico RJ, Fain J, Bauman JL. Cost-Minimization Analysis of Early, Elective Cardioversion Guided by Transesophageal Echocardiography Followed by Early Hospital Discharge for the Acute Management of Atrial Fibrillation. Pharmacotherapy 2000;20:1229-1301 [Abstract 196]. Poster presentation: American College of Clinical Pharmacy (ACCP) Annual Meeting; Los Angeles, CA. November, 2000.

4. Beitelshees A, Southworth MR, Dunlap S, DiDomenico RJ, Humma L. Cost Savings Associated with a Decreased Need for Potassium Supplementation in Heart Failure Patients on Spironolactone. Pharmacotherapy 2002;22:1327[Abstract 20]. Platform presentation: American College of Clinical Pharmacy (ACCP) annual meeting; Albuquerque, NM. October, 2002.

5. Galanter WL, DiDomenico RJ, Polikaitis A. Analysis of Medication Safety Alerts for Inpatient Digoxin Use With Computerized Physician Order Entry. J Gen Intern Med 2002;17(suppl 1):193[Abstract Tracking ID #50281]. Poster presentation: Society of General Internal Medicine. Atlanta, GA. May, 2002.

6. DiDomenico RJ, Park H, Southworth MR, Eyrich HE, Lewis RK, Finley JM, Schumock GT. Development of Guidelines for the Treatment of Acute Decompensated Heart Failure. Pharm World Sci 2004;26:A113[Abstract PT-062]. Poster presentation: 2nd American College of Clinical Pharmacy (ACCP) – European Society of Clinical Pharmacy (ESCP) International Congress on Clinical Pharmacy; Paris, France. April, 2004.

7. Schumock GT, DiDomenico RJ, Blackburn J, Walton SM, Hilleman DE. Early Therapy with Nesiritide in Hospitalized Patients with Acute Decompensated Heart Failure Associated with Reduced Costs: a


Curriculum Vitae

Page 11

Markov Analysis. Pharmacotherapy 2005;25:1493[Abstract 273E]. Poster presentation: 2005 Annual American College of Clinical Pharmacy (ACCP) meeting; San Francisco, CA. October, 2005.

8. Eyrich HM, DiDomenico RJ, Fontana DR, Kondos GT, Schumock GT. Treatment Guidelines for Acute Decompensated Heart Failure Associated with Improved Outcomes. Pharmacotherapy 2005;25:1439[Abstract 33]. Platform presentation: 2005 Annual American College of Clinical Pharmacy (ACCP) meeting; San Francisco, CA. October, 2005.

9. Blackburn J, DiDomenico RJ, Hilleman DE, Walton SM, Schumock GT. Early Therapy with Nesiritide in Hospitalized Patients with Acute Decompensated Heart Failure Associated with Reduced Costs: A Markov Analysis. J Card Fail 2005;11(suppl):S178[Abstract 332]. Poster presentation: 9th Annual Heart Failure Society of America (HFSA) Scientific Meeting. Boca Raton, FL. September, 2005.

10. DiDomenico RJ, Viana M, Fitch M, Bauman JL. A new and simple dosing algorithm for digoxin in patients with heart failure. J Card Fail 2006;12(suppl.):S85[Abstract 273]. Poster presentation: 10th Annual Scientific meeting of the Heart Failure Society of America (HFSA). Seattle, WA. September, 2006.

11. Agusala P, Fontana D, DiDomenico R, Groo V, Stamos T, Vaitkus PT. The effects of nesiritide and other vasoactive agents on renal function. J Card Fail 2006;12(suppl.):S88[Abstract 285]. Poster presentation: 10th Annual Scientific meeting of the Heart Failure Society of America (HFSA). Seattle, WA. September, 2006.

12. Blackburn JC, DiDomenico R, Walton SM, Hilleman DE, Schumock GT. Markov-based economic analysis of nesiritide in acute decompensated heart failure. Value Health. 2006;9(3):A124 [Abstract PCV20]. Poster presentation: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 11th Annual Meeting. Philadelphia, PA. May, 2006.

13. Fontana D, Vuckovic K, DiDomenico RJ, Stamos TD. Long-Term Outcomes in Patients Hospitalized for Acute Decompensated Heart Failure Stratified by Baseline Renal Function and Blood Pressure. Circulation 2006;113:e804[Abstract P88]. Poster presentation: American Heart Association’s 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke. Washington, DC. May, 2006.

14. Fitch M, DiDomenico RJ, Viana M, Bauman JL. Methods for dosing digoxin in heart failure in the modern era. Pharmacotherapy 2006;26:e41[Abstract 176]. Poster presentation: American College of Clinical Pharmacy (ACCP) 2006 Spring Practice and Research Forum (Runner Up, Best Student, Resident, Fellow Paper Award). Monterey, CA. April, 2006.

15. Perez A, DiDomenico R, Schumock GT, Theobald J, Wojtynek J. Evaluation of acute decompensated heart failure management in membership hospitals of a group purchasing organization. Pharmacotherapy 2007;27[Abstract 330]. Poster presentation: 2007 Annual American College of Clinical Pharmacy (ACCP) meeting; Denver, CO. October, 2007.

16. Vats V, DiDomenico RJ, Wojtynek J, Theobald J, Schumock GT. Hospital Policies for the Treatment of Acute Decompensated Heart Failure. Value Health. 2007;10:A53 [Abstract PCV58]. Poster presentation: 12th Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) meeting. Arlington, VA. May, 2007.

17. DiDomenico RJ, Sengupta N, Barker C. Impact of Nesiritide on Treatment of Acute Decompensated Heart Failure (ADHF): Evidence from a US Hospital Database. Value Health. 2007;10:A47 [Abstract PCV35]. Poster presentation: 12th Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) meeting. Arlington, VA. May, 2007.

18. Sauve JM, Tokumaru SM, DiDomenico RJ, Kao JA. Clinical outcomes of patients on clopidogrel with a hemorrhagic episode. Crit Care Med 2006;34:A63[Abstract 238]. Poster presentation: 36th Annual Critical Care Congress of the Society of Critical Care Medicine. Orlando, FL. February, 2007.

19. Greenhalgh E, DiDomenico RJ. Predictors of Diuretic Resistance in Patients with Acute Decompensated Heart Failure. J Card Fail 2008;14(Suppl 1):S80 [Abstract 257]. Poster presentation: 12th Annual Scientific meeting of the Heart Failure Society of America (HFSA). Toronto, Ontario, Canada. September, 2008.


Curriculum Vitae

Page 12

20. Perez A, DiDomenico RJ, Theobald J, Wojtynek J, Schumock GT. Evaluation of the Effect of Acute Decompensated Heart Failure Guidelines in Community Hospitals. Value Health. 2008;11 [Abstract PCV82]. Poster presentation: 13th Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) meeting. Toronto, Ontario, Canada. May, 2008.

21. DiDomenico RJ, Schumann HM, Bauman JL. Digoxin Toxicity in the Modern Era. Clin Tox 2008;46:368[Abstract 66]. Poster presentation: 2008 European Association of Poison Centres and Clinical Toxicologists (EAPCCT) meeting; Seville, Spain. May, 2008.

22. Bautista A, Stein BD, Lee TA, Meltzer DO, DiDomenico RJ, Krishnan JA, Schumock GT. Specificity of Administrative Data for Identifying Heart Failure Patients for Hospital Quality Performance Initiatives. Value Health 2009;12:A161[Abstract PCV107]. Poster presentation: 14th Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) meeting. Orlando, FL. May, 2009.

23. Greenhalgh E, Groo V, Stamos TD, DiDomenico RJ. Torsemide vs Furosemide Plus Metolazone for Symptomatic Heart Failure. Pharmacotherapy 2009;29:e88[Abstract 198]. Poster presentation: 2009 American College of Clinical Pharmacy (ACCP)/European Society of Clinical Pharmacy International Congress on Clinical Pharmacy. Orlando, FL. April, 2009.

24. Groo VL, Williams K, Dickens C, Stamos TD, DiDomenico RJ. Evaluation of 30-day Heart Failure Readmissions. Pharmacotherapy 2010;30:431e[abstract 234]. Poster presentation: 2010 American College of Clinical Pharmacy (ACCP) Annual Meeting. Austin, TX. October, 2010.

25. DiDomenico RJ, Na-Thalang K, Tsao Y, Groo VL, Bishop JR, Viana MAG, Bauman JL. Use of a Simplified Nomogram to Individualize Digoxin Dosing in Heart Failure Patients vs. Standard Care. Pharmacotherapy 2010;30:376e[abstract 39]. Platform presentation: 2010 American College of Clinical Pharmacy (ACCP) Annual Meeting. Austin, TX. October, 2010.

26. Schlemmer RF, Briars LA, DiDomenico RJ, Peverly SL, Rabi SM. Assessing Strategies to Encourage Student Completion of Course and Instructor Evaluations. Am J Pharm Educ 2010;74:Article 96(page 1)[Abstract]. Poster presentation: 2010 American Association of Colleges of Pharmacy Annual Meeting. Seattle, WA. July, 2010.

27. Musselman ME, Bursua AJ, DiDomenico RJ, Shroff A, Groo VL. Prescribing patterns of proton pump inhibitors in patients requiring clopidogrel post-drug eluting stent. Pharmacotherapy 2010;30:e180[Abstract 106]. Poster presentation: 2010 Amercian College of Clinical Pharmacy (ACCP) Spring Practice and Research Forum. Charlotte, NC. April, 2010.

28. Bress A, Groo VL, DiDomenico RJ, Stamos TD, Patel S, Cavallari LH. The Effect of Epithelial Sodium Channel Genotype on Loop Diuretic Requirements in Systolic Heart Failure: the First 50 Subjects. Pharmacotherapy 2011;31:e415-6[Abstract 381]. Poster presentation: 2011 American College of Clinical Pharmacy (ACCP) Annual meeting. Pittsburgh, PA. October, 2011.

29. Nutescu E, Lee YM, Dotiwala Z, Stamos T, Nehmer M, Walrath K, DiDomenico R, Ruland S, Thambi M, Galanter W. Improving the quality of heparin anticoagulation to meet Joint Commission National Patient Safety Goals. J Thromb Thrombolysis 2011;31:372 [Abstract A10]. Poster presentation: Anticoagulation Forum’s 11th National Conference on Anticoagulant Therapy. Boston, MA. May, 2011.

30. Nutescu EA, DiDomenico R, Bathija S, Grim S, Mucksavage J, Tesoro E, Ohler K, Thielke J, Chan J, Shapiro N, Engle J. Balance of academic responsibilities of clinical track pharmacy faculty in the US. Pharmacotherapy 2012;32:e190[Abstract 42]. 2012 American College of Clinical Pharmacy (ACCP) Annual meeting. Hollywood, FL. October, 2012.

31. Dickens C, Vuckovic K, Nehmer M, DiDomenico R, Kerbow D, Stamos T, Kondos G, Piano M. Improving the heart failure readmission rate at an urban medical center. West J Nurs Res 2012;34:1066-7. Epub 2012 Aug 6. PMID 22868988. Poster presentation: 36th Annual Midwest Nursing Research Society (MNRS) Doctor of Philosophy Student Poster Award (Honorable Mention). Dearborn, MI. April, 2012.

32. Dorsch MP, Lose J, DiDomenico RJ. The Effect Of Cardiovascular Credentialed Pharmacists On Process Measures and Outcomes In Myocardial Infarction and Heart Failure. Pharmacotherapy


Curriculum Vitae

Page 13

2013;33:e192.[Abstract 33E]. 2013 American College of Clinical Pharmacy (ACCP) Annual meeting. Albuquerque, NM. October, 2013.

33. Labinov Y, DiDomenico R, Nutescu EA, Cavallari LH. Comparative accuracy of pharmacogenetic warfarin dosing algorithms and the warfarin dosing label plus clinical judgement. Pharmacotherapy 2013;33:e19.[Abstract 28]. 2013 American College of Clinical Pharmacy (ACCP) Annual meeting. Albuquerque, NM. October, 2013.

34. Dorsch MP, Lose J, DiDomenico RJ. Credentialing of cardiovascular pharmacists, process measures, and outcomes. Circ Cardiovasc Qual Outcomes 2013;6(Suppl 1):A256. 2013 Quality of Care and Outcomes Research (QCOR) Scientific Sessions. Baltimore, MD. May, 2013.

35. Prieto-Centurion V, DiDomenico R, Godwin P, Grude-Bracken N, Gussin H, Jaffe HA, Joo MJ, Markos MA, Nyenhuis S, Pickard AS, Pittendrigh B, Ramey NI, Schatz B, Sullivan J, Thomashow B, Williams MV, Krishnan JA. A systematic review of interventions to reduce readmissions following COPD exacerbations. Am J Resp Crit Care Med 2013;187:A2340. 2013 American Thoracic Society (ATS) International Conference. Philadelphia, PA. May, 2013.

36. Kim K, Ardati A, DiDomenico R, Cavallari L, Touchette DR. Cost-effectiveness of genotype/phenotype driven ticagrelor versus clopidogrel selection in the patients with acute coronary syndrome. J Am Coll Cardiol 2014;63(S_12):[Abstract A24]. 63rd Annual American College of Cardiology Scientific Session & Expo. Washington, DC. March, 2014.

37. Kim K, Lee TA, Ardati AK, DiDomenico R, Touchette DR, Walton SM. Comparative effectiveness of ticagrelor vs. prasugrel in patients with acute coronary syndrome. Value Health 2015;18:A376[Abstract PCV16]. 18th Annual International Society of Pharmacoeconomic and Outcomes Research (ISPOR) European Congress. Milan, Italy. November, 2015.

38. Goncharenko A, Groo VL, Mansour I, Gans C, Stamos T, DiDomenico RJ. Hospitalization for acute heart failure provides opportunities to intensify chronic therapy for patients with heart failure with reduced ejection fraction. J Card Fail 2016;22(Suppl):S98[abstract 284]. Poster presentation: 20th Annual Scientific meeting of the Heart Failure Society of America (HFSA). Orlando, FL. September, 2016.

39. Harrington R, Kumar VM, Zueger PM, Rigoni G, Atwood AM, DiDomenico RJ, Touchette DR. Cost-utility analysis of angiotensin receptor-neprilysin inhibitor sacubitril/valsartan compared with ACE inhibitors for the treatment of chronic heart failure in the United States. Value in Health 2016;19:A49[Abstract PCV55]. Poster presentation: 21st Annual International Society of Pharmacoeconomics and Outcomes Research (ISPOR) meeting. Washington, DC. May, 2016.

40. Kim K, Ardati A, Lee TA, Touchette DR, DiDomenico R, Walton SM. Contemporary trends and predictors of antiplatelet use in patients with acute coronary syndrome following percutaneous coronary intervention. J Am Coll Cardiol 2016;67(S_13):538[Abstract 1133-018]. Poster presentation: 65rd Annual American College of Cardiology Scientific Session & Expo. Chicago, IL. April, 2016.

41. Tan AY, Mutso A, Pittendrigh B, Edwards D, McGowan D, Calhoun, E, Villareal E, Zaidi, F, Ursan I, Sullivan J, Walsh L, Williams M, Joo M, Kapheim MG, Bracken N, DiDomenico RJ, Pickard AS, Kazmi U, Prieto-Centurion V, Visvabharathy V, Krishnan JA. How often are patients admitted to the hospital for chronic obstructive pulmonary disease also treated for heart failure and vice versa. Am J Respir Crit Care Med 2017;195:A1411. American Thoracic Society (ATS) 2017. Washington, DC. May, 2017.

42. Reed BN, DiDomenico RJ, Allender JE, Coons JC, Foster JL, Moretz JD, Oliphant CS, Jennings DL. Variability in anticoagulation practices with the Impella percutaneous ventricular assist device: a survey of high-volume centers. J Heart Lung Transplant 2018;37(Suppl):S310-1[abstract 786]. 38th Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT). Nice, France. April, 2018.

Unpublished Abstracts

1. Tesoro EP, Daughton SE, DiDomenico RJ, Nutescu EA, Lewis RK.. Developing & Implementing a Pharmacist-Managed Antithrombosis Clinic. Poster presentation:


Curriculum Vitae

Page 14

• American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting; New Orleans, LA. December, 1996.

• University of Illinois at Chicago, College of Pharmacy Enrichment Day; Chicago, IL. April, 1997.

2. Daughton SE, Tesoro EP, DiDomenico RJ, Nutescu EA, Lewis RK. Developing and Implementing a Pharmacist-Managed Antithrombosis Clinic. Platform presentation: 12th Annual Great Lakes Pharmacy Resident Conference; Ypsilanti, MI. April, 1997.

3. Galanter W, Canonge L, DiDomenico RJ, Kopec K, Looi A, Paek J, Polikaitis A, Thambi M, Welch J. Alerts to Reduce Medication Errors in In-Patients with Renal Insufficiency. Poster presentation: Chicago Patient Safety Forum 2003 Showcase of Patient Safety Improvements; Chicago, IL. October, 2003.

4. Sauve J, Tokumaru S, DiDomenico R, Kao J. Clinical Outcomes of Patients on Clopidogrel with a Hemorrhagic Episode. Poster presentation: 2005 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting. Las Vegas, NV. December, 2005.

5. Lee R, Fontana D, Kondos GT, DiDomenico RJ. Impact of Nesiritide on Readmission Rates in Patients with Acute Decompensated Heart Failure. Platform presentation: 20th Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2005.

6. Fontana D, Vuckovic K, DiDomenico R, Kondos GT. The Effect of Implementation of Medical Center Guidelines on the JCAHO Quality Measures in Patients Hospitalized for HF. Platform presentation: 17th International Nursing Research Congress Focusing on Evidence-Based Practice. Montreal, Quebec, Canada. July, 2006.

7. Wiley L, DiDomenico RJ, Shapiro NL, Thambi M, Vacek L, Vitello J, Nutescu EA. Venous Thrombosis Prophylaxis in Inpatient Bariatric Surgery: A Retrospective, Cohort Evaluation. Platform presentation: 21st Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2006.

8. Salameh L, Nutescu EA, Kao J, DiDomenico RJ. Examination of Bleeding Rates in Patients on Long-term Triple Antithrombotic Therapy with Aspirin, Clopidogrel, and Warfarin following Drug-Eluting Stent Placement. Platform presentation: 21st Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2006.

9. Sauve J, Tokumaru S, DiDomenico R, Kao J. Clinical Outcomes of Patients on Clopidogrel with a Hemorrhagic Episode. Platform presentation: 21st Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2006.

10. Tsao YY, Groo VL, Bauman JL, Stamos TD, Viana MAG, DiDomenico RJ. Comparison of simplified digoxin dosing nomogram to traditional dosing methods in heart failure patients in the modern era. Platform presentation: 22nd Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2007.

11. Dreslinski JA, Paek J, Kao J, DiDomenico RJ. Comparison of clinical and economic outcomes in patients undergoing percutaneous coronary intervention with bivalirudin with or without glycoprotein IIb/IIIa inhibitors. Platform presentation: 22nd Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2007.

12. Greenhalgh E, DiDomenico RJ. Predictors of Diuretic Resistance in Patients with Acute Decompensated Heart Failure. Platform presentation: 23nd Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2008.

13. Na-Thalang K, Tsao YY, Groo VL, Bauman JL, Stamos TD, Viana MAG, DiDomenico RJ. Comparison of simplified digoxin dosing nomogram to traditional dosing methods in heart failure patients in the modern era. Platform presentation: 23nd Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2008.

14. Yu S, Galanter WL, Lambert BL, Schiff GD, Borkowsky S for the TOP-MED CERT Team. Consensus List of Priority Drug-Lab Linkages for an Inpatient Asynchronous Alert Program: Results of a Delphi Survey. Poster presentation: 2009 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting. Las Vegas, NV. December, 2009.


Curriculum Vitae

Page 15

15. Galanter W, Lambert BL, Schiff GD, Nutescu E, Yu S, DiDomenico RJ. Monitoring the Risk of Heparin-Induced Thrombocytopenia (HIT) by Linking Laboratory and Pharmacy Data. Poster presentation: Centers for Education and Research on Therapeutics (CERT) Quarterly Meeting. Washington, DC. March, 2009.

16. Bress A, DiDomenico RJ, Groo VL, Stamos TD, Cavallari LH. The Effect of Race and Genetic Variants on Diuretic Requirements in Systolic Heart Failure. Poster presentation: 2010 University HealthSystem Consortium (UHC) Pharmacy Council meeting. Anaheim, CA. December, 2010.

17. Dandeles LM, Kim KS, DiDomenico RJ. Utility of clinical and laboratory data in the identification of heparin-induced thrombocytopenia (HIT). Platform presentation: 25th Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2010.

18. Hall AD, Lee TA, DiDomenico RJ. Short-term mortality after inotropic administration in acute decompensated heart failure: a meta-analysis of randomized controlled trials. Platform presentation: 25th Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2010.

19. Musselman ME, Bursua AJ, DiDomenico RJ, Shroff A, Groo VL. Prescribing patterns of proton pump inhibitors in patients requiring clopidogrel post-drug eluting stent. Platform presentation: 25th Annual Great Lakes Pharmacy Resident Conference. West Lafayette, IN. April, 2010.

20. Lose J, Dorsch M, DiDomenico R. Restrospective cross-sectional analysis comparing hospitals with board of pharmaceutical sciences added qualifications in cardiology certified pharmacists to hospitals without pharmacists with this distinction. Poster presentation: 2011 University HealthSystem Consortium (UHC) Pharmacy Council meeting. New Orleans, LA. December, 2011.

21. Hanigan SM, DiDomenico R, Groo VL. Pharmacist-driven hospital-to-home transitional care vs. standard care in patients hospitalized for heart failure. Poster presentation: 2011 University HealthSystem Consortium (UHC) Pharmacy Council meeting. New Orleans, LA. December, 2011.

22. Labinov YA, DiDomenico RJ, Stamos TD. Clinical presentation and management of hypertensive crisis in an urban academic medical center. Poster presentation: 2011 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting. New Orleans, LA. December, 2011.

23. Hanigan SM, DiDomenico R, Groo VL. Pharmacist-driven hospital-to-home transitional care vs. standard care in patients hospitalized for heart failure. Platform presentation: 27th Annual Great Lakes Pharmacy Resident Conference. West Lafayette, Indiana. April, 2012.

24. Labinov YA, DiDomenico RJ, Stamos TD. Clinical presentation and management of hypertensive crisis in an urban academic medical center. Platform presentation: 27th Annual Great Lakes Pharmacy Resident Conference. West Lafayette, Indiana. April, 2012.

25. Prieto-Centurion V, DiDomenico R, Godwin P, Grude-Bracken N, Gussin H, Jaffe HA, Joo MJ, Markos MA, Nyenhuis S, Pickard AS, Pittendrigh B, Ramey NI, Schatz B, Sullivan J, Thomashow B, Williams MV, Krishnan JA. A systematic review of interventions to reduce readmissions following COPD exacerbations. COPD8USA Conference. Chicago, IL. June, 2013.

26. Labinov YA, DiDomenico RJ, Nutescu EA, Cavallari LH. Comparative accuracy of pharmacogenetic warfarin dosing algorithms and the warfarin dosing label plus clinical judgment. Platform presentation: 27th Annual Great Lakes Pharmacy Resident Conference. West Lafayette, Indiana. April, 2013.

27. Landup D, DiDomenico RJ. Outcomes and utilization of a pharmacy discharge service on 30-day readmission rates in patients hospitalized for acute decompensated heart failure. 28th Annual Great Lakes Resident Conference. West Lafayette, Indiana. April, 2014.

28. Harrington R, Kumar VM, Zueger PM, Rigoni G, Atwood AM, Ochieng W, DiDomenico RJ, Touchette DR. Cost-utility analysis of angiotensin receptor-neprilysin inhibitor LCZ696 to ACE inhibitors for the treatment of chronic heart failure in the United States. Student/resident/fellow non-reviewed: Abstract I20. Association of Managed Care Pharmacy (AMCP) Nexus 2015. Orlando, FL. October, 2015.

29. Ursan I, Krishnan J, Pickard AS, Calhoun E, DiDomenico R, Bahroos N, Braken N, Gussin H, Franklin C, Kazmi U, Harvey-Kodish N, Lewis S, Mcgowan D, O’Sullivan L, Prieto-Centurion V,


Curriculum Vitae

Page 16

Sullivan J, Walsh L, Williams M, Joo M. Navigating the need for patient navigators: a qualitative study to inform the design of transitional care management services for patients and their caregivers at a minority serving institution. AcademyHealth Annual Research Meeting. Minneapolis, Minnesota. June, 2015.

30. Gasbarro N, DiDomenico R. Appropriate use of intravenous diltiazem for rate control in hospitalized patients with acute-onset atrial fibrillation or atrial flutter. American College of Cardiology (ACC) 64th Annual Scientific Session and Expo (Cardiovascular Pharmacists Poster Session). San Diego, California. March, 2015.

31. Goncharenko A, DiDomenico R, Groo V, Mansour I, Gan C, Stamos, T. Trends in medication optimization during hospitalization for acute decompensated heart failure. American College of Cardiology (ACC) 65th Annual Scientific Session and Expo (Cardiovascular Pharmacists Poster Session). Chicago, Illinois. April, 2016.

32. Dwyer S, DiDomenico RJ. Impact of upstream versus deferred decision with clopidogrel administration in patients with non-ST-elevation myocardial infarction. American College of Cardiology (ACC) 66th Annual Scientific Session and Expo (Cardiovascular Pharmacists Poster Session). Washington, DC. March, 2017.

33. Metayer JR, Groo VL, Shroff A, DiDomenico RJ. Evaluation of triple vs dual antithrombotic therapy in patients with PCI: Sequence of events and its influence on prescribing patterns. American College of Cardiology (ACC) 67th Annual Scientific Session and Expo (Cardiovascular Pharmacists Poster Session). Orlando, FL. March, 2018.

RESEARCH ACTIVITIES Original Research Grant Proposals in Development 1. Identifying factors associated with optimal anticoagulation during Impella hemodynamic support.

Abiomed (Co-PIs: DiDomenico, RJ; Reed, BN) Role: Co-PI (15%) Description: We will conduct a multicenter case series of patients treated with extended Impella hemodynamic support to identify factors associated with high-quality anticoagulation.

Grant Proposals Submitted 1. Medication optimization using Smart Speakers in an Independent Living Community for Older Adults

(MedSS-IL). CHER Chicago (PI: Jarrett, JB) Role: Co-I (7%) $50,000 7/1/19 – 6/30/20 Description: We will evaluate the ability of older adult residents of an independent living community to set up and utilize smart speaker-enabled medication reminders, identify predictors of high accuracy of use, and evaluate the behavioral outcomes related to medication adherence.

2. Strategy To Overcome Pharmacist Burnout: an Online mindfulness intervention (STOPBurnOut) American Society of Health-System Pharmacists (Co-PIs: Jarrett, JB; DiDomenico, RJ) Role: Co-I (4.7%) $75,000 6/1/19 – 5/31/21 Description: We will evaluate the feasibility and effectiveness of an online mindfulness intervention for reducing the frequency and severity of burnout experienced by health-system pharmacists.

Previous Funding 1. Pharmacoeconomic analysis of three treatment strategies for the acute management of atrial

fibrillation Glaxo Wellcome, Inc. (PI: Bauman, JL) Role: Co-I (20%) $10,000 1998 – 1999

Description: We will develop a model to evaluate the costs associated with using digoxin immune Fab for the treatment of non-life-threatening digoxin toxicity.


Curriculum Vitae

Page 17

2. Pharmacoeconomic analysis of three treatment strategies for the acute management of atrial fibrillation Pharmacia & Upjohn (PI: Bauman, JL) Role: Co-I (20%) $23,500 1999 – 2000

Description: We will compare the cost-effectiveness of three treatment strategies for the acute management of patients with atrial fibrillation.

3. Evaluation of economic and clinical outcomes of guidelines for use of nesiritide in acute

decompensated heart failure in the emergency department Scios, Inc. (PI: Schumock, G) Role: Co-I (5%) $31,900 2004 – 2005

Description: We will develop guidelines for acute decompensated heart failure treatment, including the use of nesiritide.

4. Cost-effectiveness of early therapy with nesiritide in hospitalized patients with acute decompensated

heart failure: a Markov model Scios, Inc. (PI: Schumock, G) Role: Co-I (5%) $24,962 2004 – 2006

Description: We will investigate the cost-effectiveness of nesiritide in patients hospitalized for acute decompensated heart failure by developing a Markov model.

5. Improving treatment of acute decompensated heart failure in community hospitals

Scios, Inc. (PI: Schumock, G) Role: Co-I (5%) $74,630 11/2005 – 10/2006

Description: Evaluation of the impact of an educational program and prescribing guidelines on the appropriateness of use and outcomes of nesiritide in acute care hospitals

6. Tools for Optimizing Prescribing, Monitoring, and Education (TOPMED) Agency for Healthcare Research and Quality (1 U18 HS016973-01, PI: Lambert, BL) Role: Co-I (10%) $4,000,000 7/2007 – 6/2011 Description: We will develop, redesign, refine, integrate, test, deploy, and disseminate tools and training materials related to drug formularies, drug utilization review, lab-pharmacy linkages, N-of-1 trials, and pharmacoeconomics in an effort to optimize drug therapy outcomes.

7. Comparison of a simplified digoxin dosing nomogram to traditional dosing methods in heart failure patients in the modern era

American College of Clinical Pharmacy Research Institute Role: PI (20%) $20,000 10/2008 – 9/2009 Description: We are comparing the efficacy of a digoxin dosing nomogram that we developed for

patients with heart failure to traditional dosing methods. 8. The effect of race and genetic variants on diuretic requirements in patients with systolic heart failure

ASHP Foundation (PI: Bress, AP) Role: Co-I (5%) $5,000 7/2010 – 6/2011 Description: We are investigating whether race and genetic polymorphisms of the renal epithelial sodium channel influence diuretic dosing requirements in patients with heart failure.

9. PATient Navigator to rEduce Readmissions (PArTNER) Patient-Centered Outcomes Research Institute (IH-12-11-4365; PI: Krishnan, J) Role: Co-I (5%) $2,039.965 10/2013 – 11/2018 Description: We are investigating the use of community health workers as patient navigators and peer-led telephone support as a strategy to improve patient outcomes and reduce hospital readmissions at a minority-serving institution.

10. Development of an NIH Pharmacogenomics Research Network site grant application

University of Illinois at Chicago Office of the Vice Chancellor for Research (PIs: Duarte, J; Cavallari, L; Bishop, J; Kittles, R)


Curriculum Vitae

Page 18

Role: Co-I (2%) $200,000 5/2013 – 4/2015 Description: We will build upon a previous Area of Excellence (AOE) grant that established a Pharmacogenomics Working Group by expanding implementation of pharmacogenetics into clinical practice, providing increased collaborative opportunities, and demonstrate our commitment to optimizing pharmacogenomics for our unique and diverse patient population.

11. Indications-based prescribing to enhance medication CPOE safety & quality (IndicationsRX) Agency for Healthcare Research and Quality (PI: Schiff, G) Role: Invited Stakeholder (0%) $750,000 2015 – 2016 Description: We are investigating the integration of indications-based prescribing into computerized physician order entry systems as a way to enhance prescribing quality and safety.

Unfunded Grant Submissions 1. A randomized controlled, blinded, comparative effectiveness trial of an electronic medication

management assistant versus usual care in patients recently hospitalized for decompensated heart failure Agency for Healthcare Research and Quality (PI: Walton, SM). Role: Co-I (20%) $3,695,605 4/1/2010 – 3/31/2013 Description: We will conduct a prospective, randomized, clinical trial to examine the impact an electronic medication management assistant has on clinical and humanistic outcomes of patients recently discharged for the treatment of acute decompensated heart failure.

2. Pharmacy residency expansion grant (PEG) program

American Society of Health-System Pharmacists (ASHP) Foundation Role: PI (20%) $40,000 7/2013 – 6/2014 Description: We will expand the PGY2 Cardiology residency from one to two residents, incorporating increased exposure to the Pharmacogenomics Service into the experience of both residents.

3. Improving iTem writing for ExaMs in Pharmacy (ITEM-Pharm) Faculty Development Program American Association of Colleges of Pharmacy Role: PI (5%) $4,000 6/1/18 – 9/30/19 Description: We will develop and assess the impact of a faculty development program focused on improving item-writing for college of pharmacy faculty who teach in the PharmD program.

4. Clinical pharmacist burnout: a mindfulness-based approach toward mitigating symptoms. American College of Clinical Pharmacy Research Institute (PI: Jarrett, JB) Role: Co-I (5%) $30,000 9/15/18 – 9/14/19 Description: We will will develop, implement, and evaluate the effectiveness of mindfulness-based interventions in decreasing professional burnout for clinical pharmacists.

5. Medication optimization using Smart Speakers in an Independent Living community for older adults (MedSS-IL). University of Illinois Discovery Partners Institute (DPI) (Co-PIs: Jarrett, JB, DiDomenico RJ) Role: Co-PI (12%) $100,000 2/1/19 – 1/31/20 Description: We will evaluate the educational needs to support medication optimization for older adults residing in an independent living community, develop on-demand health-related educational podcasts that can be played on smart speaker devices, and characterize how older adults utilize smart speaker devices for medication optimization.

Industry-Sponsored Multi-Center Trials 1. A randomized, double blind evaluation of the efficacy and safety of two dosing regimens of Integrelin

versus placebo for reducing mortality and myocardial (re)infarction in patients with unstable angina or non-Q-wave myocardial infarction (PURSUIT Study) PURSUIT Investigators. New Engl J Med 1998;339:436-43. COR Therapeutics, Inc. Role: Local Study Monitor (0%) 1996


Curriculum Vitae

Page 19

Site: Columbia/Michael Reese Hospital; Chicago, IL.

2. Global use of strategies to open occluded coronary arteries III (GUSTO III). GUSTO III Investigators. New Engl J Med 1997;337:1118-23. Boehringer Ingelheim Role: Local Study Monitor (0%) 1996 Site: Columbia/Michael Reese Hospital; Chicago, IL.

3. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post acute coronary syndromes (The SYMPHONY Trial) SYMPHONY Investigators. Lancet 2000;335:337-45. Hoffmann-La Roche, Inc. Role: Study Coordinator/Local Study Monitor (0%) 1998 – 1999 Site: West Side Veterans Administration Medical Center; Chicago, IL.

4. A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of adenosine (Pallacor, adenosine Injection) as an adjunct to reperfusion therapy (thrombolysis or mechanical reperfusion) in the treatment of acute anterolateral myocardial infarction (AMISTAD II). AMISTAD II Investigators. J Am Coll Cardiol 2005;45:1775-80. Medco Research, Inc. Role: Study Coordinator (0%) 1999 Site: University of Illinois Hospital & Health Science System; Chicago, IL

5. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study of recombinant P-selectin glycoprotein ligand-Ig in combination with thrombolytic therapy in patients with acute myocardial infarction. Wyeth-Ayerst Research Role: Co-I (1%) $7,769 2000 – 2001 Site: University of Illinois Hospital & Health Science System; Chicago, IL

6. A phase II stratified, randomized, open-label, angiographic trial to assess the safety and efficacy of enoxaparin as an adjunct to thrombolytic with or without GP IIb/IIIa therapy, in patients with ST-elevation MI. The ENTIRE Study. ENTIRE-TIMI 23 Investigators. Circulation 2002;105:1642-9. Aventis Pharmaceuticals Role: Co-I (0%) 2000 – 2001 Site: University of Illinois Hospital & Health Science System; Chicago, IL

7. A multicenter, randomized, controlled, double-blind trial to investigate the clinical efficacy and tolerability of early treatment with simvastatin 40mg daily for 30 days, followed by simvastatin 80mg daily thereafter in tirofiban-treated acute coronary syndrome patients who have been randomized to receive enoxaparin or unfractionated heparin in conjunction with aspirin (A to Z). A to Z Investigators. JAMA 2004;292:55-64. Merck & Co., Inc. Role: Co-I (1%) $3,100 2000 – 2003 Site: University of Illinois Hospital & Health Science System; Chicago, IL

8. Acute Decompensated Heart Failure National Registry (ADHERE) Scios, Inc. Role: PI (1%) $46,000 2004 – 2006 Site: University of Illinois Hospital & Health Science System; Chicago, IL

9. Double-blind, placebo-controlled, multicenter Acute Study of Clinical Effectiveness of Nesiritide in subjects with Decompensated Heart Failure (ASCEND-HF) O’Connor CM, et al. N Engl J Med 2011;365:32-43. Scios, Inc. Role: Co-I (3%) $218,750 2007 – 2010


Curriculum Vitae

Page 20

Site: University of Illinois Hospital & Health Science System; Chicago, IL

Unfunded Research 1. Co-Investigator. Impact of the cost of prescription drugs on clinical outcomes in indigent patients with

heart disease. Completed: 1999.

2. Principal Investigator. Impact of nesiritide on readmission and mortality rates in patients with acute decompensated heart failure. Completed 2005.

3. Co-Investigator. Impact of real-time medication safety alerts on inpatient prescribing patterns of drugs using a computerized decision support system. Completed 2005.

4. Co-Investigator. Predictive value of renal dysfunction and low blood pressure on six month mortality and readmission in patients hospitalized for acute decompensated heart failure. Completed 2006.

5. Co-Investigator. Impact of treatment guidelines on compliance with JCAHO Core measures for patients hospitalized with acute decompensated heart failure. Completed 2006.

6. Co-Investigator. Impact of nesiritide on renal function in patients with acute decompensated heart failure. Completed 2006.

7. Co-Investigator. Comparison of pharmacokinetic dosing regimens for digoxin. Completed 2006.

8. Principal Investigator. Examination of bleeding rates in patients on long-term triple antithrombotic therapy with aspirin, clopidogrel, and warfarin. Completed 2007.

9. Principal Investigator. Incidence and predictors of diuretic resistance in patients with acute decompensated heart failure. Completed 2008.

10. Principal investigator. Factors associated with rehospitalization for heart failure. Completed 2010.

11. Principal investigator. Mortality associated with use of inotropic agents in patients with acute decompensated heart failure: a meta-analysis. Completed 2010.

12. Co-Investigator. Use of laboratory and pharmacy linkages to identify possible heparin-induced thrombocytopenia. Completed 2010.

13. Co-Investigator. Specificity of administrative data for identifying heart failure patients for hospital quality performance measures. Completed 2010.

14. Co-Investigator. Pharmacist-driven hospital-to-home transitional care vs. standard of care in patients hospitalized for heart failure. Completed 2012.

15. Co-Investigator. Clinical presentation and management of hypertensive crisis in an urban academic medical center. Completed 2012.

16. Co-Investigator. Prescribing patterns of proton pump inhibitors in patients having percutaneous coronary intervention on chronic clopidogrel therapy. Completed 2012.

17. Co-Investigator. Torsemide versus furosemide plus metolazone for symptomatic chronic heart failure. Completed 2012.

18. Co-Investigator. Comparative accuracy of genotype-based warfarin dosing algorithm and clinical judgment. Completed 2013.

19. Co-Investigator. Estimation of the net clinical benefit and the risk of stroke and hemorrhagic events in patients with atrial fibrillation. Completed 2013.

20. Co-Investigator. Outcomes and utilization of a pharmacy discharge service on 30-day readmission rates in patients hospitalized for acute decompensated heart failure. Completed 2014.

21. Co-Investigator. Appropriate use of IV diltiazem for rate control in patients with acute-onset atrial fibrillation or atrial flutter. Completed 2015.


Curriculum Vitae

Page 21

22. Co-Investigator. Restrospective cross-sectional analysis comparing hospitals with board of pharmaceutical sciences added qualifications in cardiology certified pharmacists to hospitals without pharmacists with this distinction. Completed 2015.

23. Co-Investigator. Trends in medication intensification during hospitalization for acute decompensated heart failure. 2015 – present.

24. Co-Investigator. Risk evaluation and prediction of cardiac events among azithromycin users (BEATS: Better Evidence of Azithromycin Treatment & Safety). 2015 – present.

25. Co-Investigator. Impella anticoagulation management survey. 2016 – 2018.

26. Co-Investigator. Impact of upstream vs deferred decision of clopidogrel administration in patients with non-ST-elevation myocardial infarction. 2016 – 2018.

27. Co-Investigator. Addition of oral metolazone to intermittent intravenous furosemide versus transition to continuous infusion furosemide in acute decompensated heart failure patients experiencing an inadequate response to therapy. Terminated 2017.

28. Co-Investigator. Cost-utility analysis of angiotensin receptor-neprilysin inhibitor sacubitril/valsartan compared to ACE inhibitors for the treatment of chronic heart failure in the United States. Completed 2017.

29. Co-Investigator. Insight into the ADP pathway inhibitor use in patients with ACS. Completed 2017.

30. Co-Investigator. Evaluation of triple vs. dual antithrombotic therapy in patients with PCI: sequence of events and it’s influence on prescribing patterns. 2017 – 2018.

INVITED LECTURES International

1. “Health economics and outcomes research workshop.” Five day, team-taught continuing education program introducing the topics of health economics and outcomes research to pharmacists and faculty members in Thailand. Khon Kaen, Thailand. January 2003. • Lecture topics: Motivations for Economic Evaluations and Outcomes Research, Cost-

Minimization Analysis, Drug Utilization Review/Evaluation, Modeling & Decision Analysis, Evaluating Pharmacoeconomic Literature, Clinical Pathways, Applying Results.

2. “Transitions of care and pharmacist services” Given as part of the American College of Clinical Pharmacy (ACCP) 2015 From Theory to Bedside: Clinical Reasoning Series entitled “Heart Failure: Current and Emerging Management Strategies” during the 2015 ACCP Global Conference on Clinical Pharmacy: 0.6 CEU (ACPE Universal Program # 0217-0000-15-111-L01-P). San Francisco, CA. October, 2015.

3. “Treatment of acute cardiovascular diseases”. 3-day series of lectures and case workshops as part of the Hong Kong University Master of Clinical Pharmacy program. Pokfulam, Hong Kong. October, 2017. • Lecture topics: Cardiovascular Assessment, IV Vasoactive Drugs, Hypertensive Crisis, Acute

Coronary Syndrome, Acute Decompensated Heart Failure, Pharmacotherapy of Shock, Acute Treatment of Atrial Fibrillation & Atrial Flutter.

4. “Starting with the end in mind: Planning & executing your research project”. Presented as part of a session entitled “Perfecting your poster presentations” during the 2018 American College of Clinical Pharmacy (ACCP) Global Conference: 1.5 CEU. Seattle, WA. October, 2018.

National 1. “Late-Breaking clinical trials in cardiovascular pharmacotherapy: ELITE II Study.” American College

of Clinical Pharmacy (ACCP) Annual Meeting: 0.2 CEU (ACPE Universal Program #217-000-00-054-L01). Los Angeles, CA. November, 2000.

2. “Innovative reimbursement strategies in acute coronary syndrome.” Satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.15 CEU (ACPE Universal Program #: 510-000-01-035-L01). New Orleans, LA. December, 2001.


Curriculum Vitae

Page 22

3. “Combining GP IIb/IIIa inhibitors with fibrinolytics in acute ST segment elevation MI.” American College of Clinical Pharmacy (ACCP) Spring Practice & Research Forum: 0.275 CEU (ACPE Universal Program #217-000-02-017-L01). Savannah, GA. April, 2002.

4. “The use of colloids and antithrombotics during open-heart surgery.” American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.3 CEU (ACPE Universal Program #204-000-02-238-L01). Atlanta, GA. December, 2002

5. “The closed loop medication management experience.” Series of demonstrations showing the utility of the decision support mechanisms developed at the University of Illinois Medical Center. Healthcare Information and Management Systems Society 2003 Annual Conference & Exhibition. San Diego, CA. February, 2003.

6. “Guidelines for the management of acute decompensated heart failure in the emergency department or observation unit.” Mercy Resource Management,Inc. Clinical Resource Committee. San Diego, CA. May, 2003.

7. “Acute decompensated heart failure: can I get some guidance?” Satellite symposium at the American College of Clinical Pharmacy (ACCP) Annual Meeting: 0.2 CEU (ACPE Universal Program #221-000-03-036-L01). Atlanta, GA. November, 2003.

8. “Acute decompensated heart failure: where does nesiritide fit in?” Satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.2 CEU (ACPE Universal Program #221-000-03-036-L01). New Orleans, LA. December, 2003.

9. “Strategies for preventing atrial fibrillation in the perioperative setting.” American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.3 CEU (ACPE Universal Program #204-000-03-239-L01). New Orleans, LA. December, 2003.

10. “Acute decompensated heart failure: evolution of treatment guidelines.” Guest speaker at the Scios, Inc. National Sales Meeting 2004. New Orleans, LA. April, 2004.

11. “Acute decompensated heart failure: early goal directed therapy.” 3 separate live audio teleconferences to members of the Premier, Inc. healthcare system: 0.1 CEU (ACPE Universal Program # 221-000-04-014-L01). July, 2004.

12. “The pharmacist’s perspective on emergency management of heart failure.” Live webcast broadcast nationally to emergency medicine clinicians across the United States as part of a series from the Cleveland Clinic Center: 0.15 CEU (ACPE Universal Program #073-999-04-135-C01). Cleveland, OH. October, 2004.

13. “Acute decompensated heart failure: proposed treatment guidelines.” Focus Group on the IHN Perspectives of Disease State Management of Congestive Heart Failure for members of Novation/VHA/UHC. Sponsored by Scios, Inc.. Irving, TX. March, 2005.

14. “Hypertension, metabolic syndrome, and JNC guidelines: reassessing treatment guidelines.” American Pharmacists Association (APhA) Foundation National Clinical Issues Forum on Metabolic Syndrome: 0.1 CEU (ACPE Universal Program #202-000-05-168-L01). Lake Bluff, IL. May, 2005.

15. “Evaluating acute decompensated heart failure treatment: from nesiritide MUE to ADHF guidelines.” Scios, Inc. National Pharmacy Advisory Board. San Francisco, CA. June, 2005.

16. “Managing ADHF: resource utilization and cost containment.” Live webcast broadcast nationally to heart failure clinicians across the United States: 0.15 CEU. July, 2005.

17. “Acute decompensated heart failure: strategies to improve clinical and economic indicators.” Live webcast broadcast nationally to members of McKesson Medication Management, LLC and Purchasing Alliance for Clinical Therapeutics. Continuing education credit: 0.1 CEU. August, 2005.

18. “Pathway development and pharmacoeconomics of acute decompensated heart failure treatment.” Presented & chaired a satellite symposium on “Current and Emerging Issues in the Management of Acute Decompensated Heart Failure” for Continuing Education: 0.2 CEU (ACPE Universal Program #204-000-05-419-L01). American College of Clinical Pharmacy (ACCP) Annual Meeting. San Francisco, CA. October, 2005.


Curriculum Vitae

Page 23

19. “Using critical pathways and pharmacoeconomics to guide ADHF treatment decisions” Presented & chaired a satellite symposium on “Acute Decompensated Heart Failure: Current and Emerging Issues Influencing Treatment Strategies” for Continuing Education: 0.25 CEU (ACPE Universal Program #204-000-05-420-L01). American Society of Health-System Pharmacy (ASHP) Midyear Clinical Meeting. Las Vegas, NV. December, 2005.

20. “Pharmacologic management of atrial fibrillation.” American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.3 CEU (ACPE Universal Program #204-000-05-218-L01). Las Vegas, NV. December, 2005.

21. “Current controversies in the management of acute decompensated heart failure.” Presented as a national teleconference for pharmacists. April, 2006.

22. “The nesiritide controversy: if there’s smoke, is there fire?” Satellite symposium at the American College of Clinical Pharmacy (ACCP) Annual Meeting: 0.2 CEU (ACPE Universal Program # 786-000-06-010-L01). St. Louis, MO. October, 2006.

23. “Future directions in ADHF treatment: unresolved issues and emerging evidence.” Satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.25 CEU (ACPE Universal Program # 204-000-06-459-L01). Anaheim, CA. December, 2006.

24. “Determining the value of pharmacy intervention/services in an acute care hospital aetting” American College of Clinical Pharmacy (ACCP) Spring Practice & Research Forum: 0.2 CEU (ACPE Universal Program #217-000-08-030-L04-P). Phoenix, AZ. April, 2008.

25. “Update in the management of chronic stable angina and the role of the pharmacist.” American Pharmacists Association (APhA) Annual Meeting: 0.2 CEU (ACPE Universal Program #217-000-08-030-L04-P). San Antonio, TX. April, 2009.

26. “Implementing quality measures across the continuum: success in the inpatient setting.” American College of Clinical Pharmacy (ACCP) Annual Meeting: 0.15 CEU (ACPE Universal Program #0217-0000-12-105-L04-P). Hollywood, FL. October, 2012.

27. “Heart health: hypertension, cardiac, and hypercholesterolemia.” Gerontological Advanced Practice Nurses Association (GAPNA) Pre-Conference Workshop. Chicago, IL. September, 2013.

28. “Perspectives on reducing readmission.” 2013 Heart Failure Society of America Heart Failure (HFSA) Comprehensive Review & Update. Chicago, IL. November, 2013.

29. “Therapeutic considerations in heart failure patients with anemia.” Presented and moderated “How to manage comorbidities in heart failure: depression, sleep apnea, and anemia.” 2013 Heart Failure Society of America (HFSA) Heart Failure Comprehensive Review & Update. Chicago, IL. November, 2013.

30. “Evaluating the evidence: clinical guidelines on secondary prevention.” Satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.2 CEU (ACPE Universal Program #0245-0000-13-023-L01-P). Orlando, FL. December, 2013.

31. “A pharmacist’s perspective on dosing considerations for novel oral anticoagulants in venous thromboembolism and prevention of atrial fibrillation-related stroke.” Panelist for a videotaped continuing education satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.050 CEU (ACPE Universal Program #0461-0000-14-004-H01-P). Orlando, FL. December, 2013.

32. “Hypertensive emergencies.” Panelist for this Pharmacology Program as part of the 63rd Annual American College of Cardiology (ACC.15) Scientific Sessions. Washington, DC. March, 2014.

33. “The beta-adrenergic receptor post-MI: beta-blocker use should continue.” Part of a pro/con debate. 64th Annual American College of Cardiology Scientific Session & Expo. San Diego, CA. March, 2015.

34. “New cardiovascular drugs: out with the old, in with the new?” Live webinar to members of Community Health Systems. ProCE, Inc.: 0.2 CEU. Bartlett, IL. May, 2015.


Curriculum Vitae

Page 24

35. “Case discussion-clinical conundrums”. Panelist for session at the 19th Annual Heart Failure Society of America (HFSA) Scientific Meeting. National Harbor, MD. September, 2015.

36. “PCSK9 inhibitors and entresto: who should get these expensive new drugs and what are the economic implications?” Panelist for this Pharmacology Program as part of the 65rd Annual American College of Cardiology (ACC.16) Scientific Sessions. Chicago, IL. April, 2016.

37. “Treatment considerations in HF patients with cognitive disorders.” Presented as part of the Clinical Fundamentals III session entitled “Cognitive Deficits in HF: Chicken or the Egg?” 20th Annual Heart Failure Society of America (HFSA) Scientific Meeting. Orlando, FL. September, 2016.

38. “Contemporary approaches to the management of chronic heart failure: an overview.” American Society of Health-System Pharmacists (ASHP) Advantage webinar: 0.1 CEU (ACPE Universal Program #0204-0000-16-463-L01-P; 0204-0000-16-463-H01-P). Chicago, IL. October, 2016.

39. “Do’s and don’ts during peer review.” Presented and served on panel for session entitled “The Best of Times, The Worst of Times: Navigating the Peer Review Process.” American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.15 CEU (ACPE Universal Program #0271-0000-16-155-L04-P). Las Vegas, NV. December, 2016.

40. “New and emerging strategies for the treatment of chronic heart failure: a clinical case studies workshop.” Presented and moderated satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.15 CEU (ACPE Universal Program #0204-0000-16-467-L01-P; 0204-0000-16-467-H01-P). Las Vegas, NV. December, 2016.

41. “The pharmacist’s role in optimizing outcomes for heart failure.” Presented as part of the Directions in Pharmacy Spring Series and Webinar. Pharmacy Times Continuing Education (PTCE): 0.1 CEU (ACPE Universal Program #0290-0000-17-016-L01-P). Webinar (August, 2017).

42. “Improving the management of chronic heart failure during transitions of care.” American Society of Health-System Pharmacists (ASHP) Advantage webinar: 0.1 CEU (ACPE Universal Program #0204-0000-17-436-L01-P; 0204-0000-17-436-H01-P). Chicago, IL. September, 2017.

43. “Cardiology PRN focus session—practical approaches to heart failure management across the continuum of care”. Moderated session at the American College of Clinical Pharmacy (ACCP) Annual Meeting: 0.15 CEU (ACPE Universal Program #0217-0000-17-159-L01-P). Phoenix, AZ. October, 2017.

44. “Better management of chronic heart failure through better transitions of care: a clinical case studies workshop.” Presented and moderated satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.15 CEU (ACPE Universal Program #0204-0000-17-437-L01-P; 0204-0000-17-437-H01-P). Orlando, FL. December, 2017.

45. “Challenging cases in diabetes management in heart failure.” Presented as part of a symposium entitled “750 – Sweetening the Pill: New Options for Treating Diabetes in Heart Failure” at the 67th Annual Scientific Session & Expo of the American College of Cardiology (ACC.18). Orlando, FL. March, 2018.

46. “To dig or not to dig.” Presented as part of the session entitled “Help or Harm? Common Controversies in the Management of HF” at the 22nd Annual Heart Failure Society of America (HFSA) Scientific Meeting. Nashville, TN. September, 2018.

47. “Sodium restriction in heart failure: worth its salt? Pro.” Presented as part of the session entitled “Fact or Fiction: Clinical Controversies in Heart Failure” at the American Heart Association (AHA) Scientific Sessions 2018. Chicago, IL. November, 2018.

48. “Getting back to basics: The evidence for what works in the management of chronic heart failure.” Presented and moderated satellite symposium at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting: 0.15 CEU (ACPE Universal Program #0204-0000-18-447-L01-P; 0204-0000-18-446-H01-P). Anaheim, CA. December, 2018.


Curriculum Vitae

Page 25

49. “Ask the experts: building a toolkit for managing heart failure.” American Society of Health-System Pharmacists (ASHP) Advantage webinar: 0.1 CEU (ACPE Universal Program #0204-0000-19-405-H01-P). Chicago, IL. March, 2019.

Local/Regional

1. “Does Growth Hormone Have a Role in the Treatment of Congestive Heart Failure?” University of Illinois at Chicago, College of Pharmacy. Chicago, IL. November, 1996.

2. “Are Appetite Suppressants (Anorexics) Safe in Patients with Cardiovascular Disease?” Michael Reese Hospital. Chicago, IL. May, 1997

3. “Use of Digoxin Immune Fab for Non-Life-Threatening Digoxin Toxicity.” University of Illinois at Chicago College of Medicine, Section of Cardiology Research Conference. Chicago, IL. September, 1998.

4. “Digoxin Immune Fab: An Alternative to Minimize the Costs of Treating Non-Life-Threatening Digoxin Intoxication.” February, 1999.

• University of Nebraska (Omaha, NE), University of Missouri-Kansas City (Kansas City, MO), & Texas Tech University (Amarillo, TX).

5. “Clinical Pharmacology of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors.” Illinois Pharmacy Spring Congress: 0.15 CEU (ACPE Universal Program Number 121-888-99-024-L01b). Springfield, IL. April, 1999.

6. “Glycoprotein IIb/IIIa Inhibitors: Where Do They Fit In?” University of Illinois at Chicago College of Pharmacy: 0.3 CEU (ACPE Universal Program Number 016-000-99-050-L04). Oak Brook, IL. November, 1999.

7. “Tikosyn™ (dofelitide) Clinical Profile.” Tikosyn™ Faculty Educator as part of the Tikosyn™ Medical Education Program regionally within the Midwestern United States. July, 2000 – 2001.

8. “Lipid-Lowering Drugs & Cardiovascular Event Reduction: Beyond Improved Lipid Profiles.” Illinois Pharmacy Fall Congress: 0.1 CEU (ACPE Program Number 135-121-00-068-L01). Oakbrook, IL. September, 2000.

9. “Pharmacology Update for the Perfusionist: New Antithrombotic Drugs.” Chicago Educational Symposium for Cardiac Perfusionists. Chicago, IL. October, 2000.

10. “Diagnosis and Treatment of Hypertension.” Novartis II and Novartis III Center of Excellence Design. Chicago, IL. February, 2001 - 2006.

11. “Building Community…Using Mentoring.” University of Illinois at Chicago College of Pharmacy 2001 Faculty Retreat: 0.15 CEU (ACPE Universal Program Number 016-000-01-026-L04). St. Charles, IL. May, 2001.

12. “Antiplatelet Therapy in the Management of Acute Coronary Syndromes: Use of Chronic Medications for Acute Coronary Syndromes: Antiplatelets & Statins.” Phi Delta Chi Alumni Association: 0.15 CEU (ACPE Universal Program Number 316-000-99-022-L01). Oak Brook, IL. November, 2001.

13. “Heparin-Induced-Thrombocytopenia and Anticoagulation During Cardiopulmonary Bypass.” Illinois State Perfusion Society Meeting. Chicago, IL. April, 2002.

14. “Acute Decompensated Heart Failure: Current Therapies and Proposed Guidelines.” Mercy Resource Management, Inc. Clinical Resource Committee. Chicago, IL. April, 2003.

15. “Medications Ordered During Pregnancy that Affect Cardiac Function.” Nursing Staff Development. University of Illinois at Chicago, College of Nursing. Chicago, IL. June, 2003 - 2005.

16. “Pharmacology of Vasoactive & Antiarrhythmic Drugs Commonly Used in the ICU.” Nursing Staff Development Critical Care. University of Illinois Medical Center. Chicago, IL. June, 2003 – 2008.

17. “Rational Approach to Vasoactive Pharmacotherapy.” University of Illinois at Chicago: 0.1 CEU (ACPE Universal Program Number 121-000-03-045-L01). Chicago, IL. July, 2003.


Curriculum Vitae

Page 26

18. “Acute Decompensated Heart Failure: Early Goal Directed Therapy”: 0.2 CEU (ACPE Universal Program #221-000-03-036-L01). Memphis, TN. March, 2004.

19. “Metabolic Syndrome: A New Target in Preventative Cardiology.” Illinois Council for Health-System Pharmacists (ICHP) Spring Meeting: 0.3 CEU (ACPE Universal Program Number 121-000-04-012-L01). Springfield, IL. March, 2004.

20. “Medication Madness: New Drugs for Cardiac Care.” Guest speaker at the Minneapolis Heart Institute 6th Annual Hutchinson Regional Cardiovascular Nursing Conference. Hutchinson, MN. April, 2004.

21. “Opening the Therapeutic Window in Acute Decompensated Heart Failure: Closing in on the Value of Nesiritide.” University Pharmacotherapy Associates, LLC: 0.1 CEU (ACPE Universal Program # 786-000-03-006-L01). May – October, 2004.

• Indianapolis, IN; Suffern, NY; Providence, RI; Palos Park, IL; Princeton, NJ (New Jersey Society Health-System Pharmacy North Central Chapter meeting).

22. “Metabolic Syndrome: A New Target in Preventative Cardiology.” Abbott Cardiovascular Medical Science Liaisons. Chicago, IL. July, 2004.

23. “Treatment Guidelines for Acute Decompensated Heart Failure: Design and Implementation.” Dearborn, MI. September, 2004.

24. “Anticoagulation Interruptus: Low-Molecular-Weight Heparin Bridging in Patients with Prosthetic Heart Valves.” University of Illinois at Chicago College of Medicine, Section of Cardiology for CME credit. Chicago, IL. November, 2004.

25. “Life as a Clinical Pharmacist.” American Pharmaceutical Association Academy of Student Pharmacists at the University of Illinois at Chicago College of Pharmacy. Chicago, IL. November, 2004.

26. “Acute Myocardial Infarction: Get with the Guidelines!” University of Illinois at Chicago: 0.1 CEU (ACPE Universal Program Number 121-999-05-031-L01). Chicago, IL. March, 2005.

27. “Therapeutic Advances in Acute Decompensated Heart Failure.” University Pharmacotherapy Associates, LLC: 0.1 CEU (ACPE Universal Program # 786-000-03-006-L01). April, 2005 – September, 2005.

• Southfield, Michigan; Oklahoma City, Oklahoma; Carle Place, New York (c/o Long Island Society of Health-System Pharmacy monthly meeting); Libertyville, IL; Rosemont, Illinois.

28. “Evaluating Acute Decompensated Heart Failure Treatment: From Nesiritide MUE to ADHF Guidelines.” Scios, Inc. Regional Pharmacy Advisory Board. Chicago, IL. July, 2005.

29. “The Nesiritide Controversy: Media-Based Medicine or Evidence-Based Medicine.” University of Illinois at Chicago College of Medicine, Section of Cardiology. Chicago, IL. September, 2005.

30. “Achieving Hemostasis in the Critically Ill Patient.” Program chair & moderator: 0.2 CEU (ACPE Universal Program Number 221-000-05-045-L01). Oak Brook, IL. October, 2005.

31. Acute Decompensated Heart Failure: Strategies to Improve to Improve Clinical and Economic Indicators.” Consorta 2005 Annual Resource Management Conference: 0.1 CEU. Chicago, IL. October, 2005.

32. “Influence of Treatment Strategy on Six-Month Mortality and Readmission in Patients Hospitalized for Acute Decompensated Heart Failure.” University of Illinois at Chicago Department of Pharmacy Practice Research Seminar series. Chicago, IL, January, 2006.

33. “Acute Decompensated Heart Failure: Lessons from ADHERE®”. Oak Brook, IL. June, 2006. 34. “Digoxin Dosing in the Modern Era for Patients with Chronic Heart Failure.” University of Illinois at

Chicago College of Medicine, Section of Cardiology for CME credit. Chicago, IL. November, 2006. 35. “Diuretic Resistance in Heart Failure.” University of Illinois at Chicago College of Medicine, Section of

Cardiology for CME credit. Chicago, IL. January, 2008.


Curriculum Vitae

Page 27

36. “Engaging Clinical Faculty in Scholarship.” 2008 University of Illinois College of Pharmacy Faculty Retreat: 0.2 CEU (ACPE Universal Program Number 016-000-08-017-L04-P). Fontana, WI. May, 2008.

37. “PDAT Coordination – Developing Standard Practices.” 2010 University of Illinois College of Pharmacy Faculty Retreat: 0.2 CEU (ACPE Universal Program Number 016-000-08-017-L04-P). Fontana, WI. May, 2010.

38. “Medications and the Perfusionist: Is the Glass Half-Full or Half-Empty?” Illinois State Perfusion Society Meeting. Oak Brook, IL. October, 2010.

39. “Heparin Grand Rounds.” Nursing Staff Development. University of Illinois Medical Center. Chicago, IL. March, 2011.

40. “Pharmacotherapy for Acute Coronary Syndromes & Acute Decompensated Heart Failure.” University of Illinois at Chicago College of Medicine Section of Cardiology. Chicago, IL. September, 2011.

41. “The Role of a Facilitator to Engage Students in Recitation Sessions.” University of Illinois at Chicago College of Pharmacy: 0.2 CEU (ACPE Universal Program Number 016-000-11-136-L01-P). Rockford, IL. October, 2011.

42. “New and Emerging Antithrombotic Therapies for Patients with Acute Coronary Syndrome.” 2011 University of Illinois at Chicago College of Pharmacy CPE Fall Summit: 0.1 CEU (ACPE Universal Program Number 016-000-11-113-L01-P). Chicago, IL. October, 2011.

43. “Health Professions Student Council Leadership Series Round Table.” Health Professions Student Council members: role of the clinical pharmacist. University of Illinois at Chicago College of Pharmacy. Chicago, IL. November, 2011.

44. “UIC Curriculum Revision Update.” Presented to University of Illinois at Chicago College of Pharmacy National Advisory Board. Chicago, IL. April, 2012.

45. “Writing Quality Self-Assessment Questions.” Part of panel discussion. University of Illinois at Chicago College of Pharmacy Residency Teaching Program. Chicago, IL. May, 2012.

46. “Implementation of Clopidogrel Pharmacogenetics at the University of Illinois Hospital & Health Sciences System.” Part of panel discussion. University of Illinois at Chicago College of Pharmacy: 0.1 CEU (ACPE Universal Program Number 0016-0000-12-082-L01-P). Chicago, IL. June, 2012.

47. “Novel Oral Anticoagulants for Venous Thrombosis and Atrial Fibrillation: Implications for Clinical Practice.” University of Illinois at Chicago College of Pharmacy: 0.1 CEU (ACPE Universal Program Number 0016-0000-12-082-L01-P). Chicago, IL. August, 2012.

48. “Don’t Be Left Out in the Cold: Pharma Update.” 5th Annual Illinois Chapter American College of Cardiology (ACC) Cardiac Care Associate Symposium. Lombard, IL. November, 2012.

49. “Balance of Academic Responsibilities of Clinical Track Pharmacy Faculty in the US. University of Illinois at Chicago College of Pharmacy Department of Pharmacy Practice Faculty Development Seminar Series. Chicago, IL. February, 2013.

50. “Standardizing the Principles of Drug Action and Therapeutics (PDAT) series of courses in the PharmD curriculum”. 2013 University of Illinois College of Pharmacy Faculty Retreat. Fontana, WI. May, 2013.

51. “Transitions: Preparing Your Learners for Their Next Steps”. 2013 University of Illinois at Chicago College of Pharmacy Preceptor Conference: 0.1 CEU (ACPE Universal Program Number 0016-0000-13-104-L04-P). Chicago, IL. May, 2013.

52. “CAPs: Creating Anticoagulation Plans to Prevent Stroke in Patients with Atrial Fibrillation.” Paradigm Medical Communications. Austin, TX; Quincy, IL. June – August, 2013.

53. “Opportunities for Pharmacy to Impact Inpatient Quality Measures.” Illinois Council of Health System Pharmacists (ICHP) 2013 Annual Meeting: 0.1 CEU (ACPE Universal Program Number 0121-0000-13-053-L05-P). Oakbrook Terrace, Illinois. September, 2013.


Curriculum Vitae

Page 28

54. “UIC New Curriculum Preview.” 2015 University of Illinois at Chicago College of Pharmacy Preceptor Conference: 0.05 CEU. Chicago, IL. May, 2015.

55. “Curricular Revision Update”. 2015 University of Illinois College of Pharmacy Faculty Retreat. Fontana, WI. May, 2015.

56. “Curricular Change at UIC: Fruits of a Slow but Steady Process of Faculty Engagement.” University of Wisconsin School of Pharmacy. Madison, WI. November, 2015.

57. “JNC 8 Guideline for Hypertension: Was It Worth The Wait?” Rockford Memorial Hospital Grand Rounds. Rockford, IL. May, 2016.

58. “Practice-Based Approach to Heart Failure Research.” University of Nebraska College of Pharmacy. Omaha, NE. March, 2016.

59. “The pharmacist’s role in optimizing outcomes for heart failure.” Presented as part of the Directions in Pharmacy Spring Series and Webinar. Pharmacy Times Continuing Education (PTCE): 0.1 CEU (ACPE Universal Program #0290-0000-17-016-L01-P). Princeton, NJ (March, 2017); Dallas, TX (April, 2017).

60. “Using Practice-Based Research to Resolve Drug-Related Problems & Identify Opportunities for Pharmacists”. Haim G. and Jane Graumann Nagirner Weinstein Symposium Series Speaker. Rosalind Franklin University of Medicine and Science College of Pharmacy. North Chicago, IL. November, 2017.

61. “Developing successful research collaborations: turning practice into scholarship.” Faculty development seminar for members of the University of Illinois at Chicago College of Pharmacy Department of Pharmacy Practice. Chicago, IL. April, 2018.

62. “Lessons in precepting pharmacy trainees.” Palmetto Health Richland. Columbia, SC. October, 2018.

63. “Clinical controversies in the management of acute heart failure.” South Carolina Society of Health-System Pharmacists (SCSHP) Fall meeting: 0.1 CEU. Columbia, SC. October, 2018.

64. “Improving transitions of care in heart failure: the role of health-systems and community pharmacists.” Presented as part of the Directions in Pharmacy Spring Series and Webinar. Pharmacy Times Continuing Education (PTCE): 0.1 CEU (ACPE Universal Program #0290-0000-19-033-L01-P). Chicago, IL (March, 2019); Anaheim, CA (April, 2019); Nashville, TN (May, 2019), New Brunswick, NJ (June, 2019).

ORGANIZATIONAL MEMBERSHIPS 1996 – 2010 Illinois Council of Health-System Pharmacists (ICHP) 2008 – 2009 ICHP/Missouri Society of Health-System Pharmacists

(MSHP) 2009 Spring Meeting Planning Committee

1996 – present American Society of Health-System Pharmacists (ASHP) 2000 – 2006 Network Resource Contact

2005 – present Section on Clinical Specialists and Scientists 2006 – 2009 ASHP Research and Education Foundation

Antithrombotic Pharmacotherapy Traineeship Main Co-Preceptor

2013 Survey Panel for the Pharmacy Forecast 2014 – 2018 report (ASHP Foundation Center for Health-System Pharmacy Leadership)

2013 PGY2 Cardiology Pharmacy Residency program Site Surveyor

2016 – 2017 PGY2 Cardiology Residency Goals & Objectives Revision Workgroup (ACCP representative)

1997 – present American College of Clinical Pharmacy (ACCP) 1997 – present Cardiology PRN


Curriculum Vitae

Page 29

2008 – 2009 Editorial liaison for Cardiology Today 2008 – 2012 Awards and Recognition Committee 2011 Cardiology PRN & American Heart

Association Focus Session Content Reviewer

2012 Heart to Heart program 2012 – 2013 Expenditures Committee 2012 – 2013 2013 Focus Session Programming

Committee 2013 – 2014 Budget and Finance Committee 2014 – 2015 Research and Scholarship Committee 2018 – present 2014 – present Mentorship Program 2015 – 2017 Programming Committee 2017 – 2018 Nominations Committee 2019 – present eJournal Club mentor

1997 – 2007 Critical Care PRN 2001 – 2007 Outcomes and Economics PRN 2007 – 2009 Heart Failure Traineeship Site Director 2012 Clinical Pharmacy Challenge Item Writer 2012 – 2018 Practice-Based Research Network (PBRN),

2014 – 2018 Community Advisory Panel 2013 Inpatient Clinical Pharmacist Focus

Group 2013 – 2014 Certification Affairs Committee 2016 Grant reviewer, Research Institute Futures Grants &

Junior Investigator Grant 2019 Clinical Research Challenge Review Committee

2001 – present Rho Chi Society, Phi Chapter

2004 – 2008 University Pharmacotherapy Associates, LLP (UPA) National Consensus Faculty

2004 – 2006 Acute Decompensated Heart Failure programs 2007 – 2008 Acute Coronary Syndrome programs

2005 – present Heart Failure Society of America (HFSA) 2014 – present Research Committee 2016 – 2017 Annual Speed Mentoring Session Mentor 2018 – present Programming Committee (2019 Annual Meeting)

2007 National Association of Boards of Pharmacy® (NABP®) Item Writing Workshop for the North American Pharmacist Licensure Examination™ (NAPLEX®)

2011 – 2014 American Heart Association (AHA), Midwest Affiliate 2002 – 2004 American Heart Association (AHA) Get With the Guidelines

Consortium 2011 – 2014 Council on Clinical Cardiology

2011 – 2014 Council on Quality of Care and Outcomes Research

2012 – 2015 Phi Lambda Sigma Pharmacy Leadership Society, Alpha lota chapter 2013 – 2015 Lunch with a Pharmacist Host


Curriculum Vitae

Page 30

2012 – present American College of Cardiology (ACC) 2012 – present Cardiovascular Team Member Section 2014 – present Clinical Pharmacists Work Group 2015 – present ACC Cardiovascular Pharmacists Poster Session

Planning Committee 2017 – present CardioSurve Research Panel

2017 – present Board of Pharmacy Specialties (BPS) 2017 – present Appointed member, Inaugural BPS Specialty Council on

Cardiology

2018 – present American Association of Colleges of Pharmacy (AACP)

COMMITTEE MEMBERSHIP University of Illinois Hospital & Health Sciences Center

1999 – 2002 6WSD/CICU Quality Assurance/Improvement Committee 1999 – 2004 Hospital Pharmacy Services Committees 2003 – 2004 Pharmacy Advisory Group

2003 – 2004 Ad-Hoc Committee for medications requiring special monitoring

2000 – 2001 Medication Use Evaluation Committee 1999 – 2000 Pharmacy Council

1999 – 2005 Emergency Cardiac Care Committee 2004 – 2005 Protective Code Subcommittee 2001 – 2002 JCAHO Patient Assessment Task Force 2001 – 2004 Clinical Decision Support Committee 2003 – 2006 Cardiovascular Quality Improvement Committee

Departments of Medicine (Section of Cardiology) & Surgery (Division of Cardiothoracic Surgery)

2003 – 2013 Cardiovascular (CV) Quality Improvement (QI) Committee 2009 – 2010 CV QI Committee Subcommittee on 30-day

readmissions 2005 Sentinel Event Clinical Review Team 2006 – 2007 Perioperative Beta-Blockade Committee 2009 – 2014 Journal Club Facilitator

University of Illinois at Chicago, College of Medicine Housestaff Physicians 2010, 2014, 2017 Key Content Expert, G-1.01. Acute Coronary Syndromes Clinical Care Guideline 2011, 2014 Key Content Expert, G-1.02. Adult Heart Failure Management Clinical Care

Guideline 2012 – 2013 Healthcare Delivery Grants and Contracts Review Board 2013 – 2016 Heart Failure Readmission Team 2013 – 2014 Readmissions Clearinghouse 2013 – 2014 Project BOOST Core Team 2018 – present Discovery Partners Institute (DPI) Health Topic Advisory Board

(Illinois Innovation Network, IIN)

University of Illinois at Chicago College of Pharmacy

2000 – present Department of Pharmacy Practice Committees 2000 – 2007 Pharmacy Practice Resident Seminar Evaluation

Committee


Curriculum Vitae

Page 31

2000 – present Various Search Committees 2005 Strategic Planning Committee 2005 Part-Time Faculty Ad-Hoc Committee 2006 – 2012, Faculty Advisory Committee 2014 – present 2006 – 2008 Educational Policy Committee 2007 – 2009 Residency Noon Report Committee 2008 – 2012 Institutional Review Board Internal Review Committee 2009 – 2010, 2013 Research Strategic Planning Committee 2013 – 2015 Mid-career Faculty Development Committee 2014 – 2016 Promotion and Tenure Ad Hoc Committee 2015 – present Promotion and Tenure Committee

2004 – 2006, Educational Policy Committee (elected member, 2008 – 2018) 2008 – 2018 2004 Pharmacy Practice Subcommittee

2005 – 2006 Pharmacokinetics Working Group 2008 – 2015 Rockford Expansion Subcommittee 2008 – 2012 Teaching Evaluation Subcommittee 2010 – 2015 Rockford Policies Subcommittee 2015 – 2018 New Curriculum Implementation Subcommittee

2006 – 2007 American Council for Pharmaceutical Education (ACPE) Self-Study Committee

2007 – 2012 Residency Research Committee 2010 – 2011 Clinical Tenure Track Ad-hoc Committee

2008 – 2018 Student Faculty Relations Committee 2008 – 2009 Thesis Dissertation Defense Committee (Candidate: Alexandra Perez) 2008 – 2010 Continuing Education Advisory Committee 2009 Assistant Head for Academic Affairs Search Committee 2010 – 2011 Task Force on Teaching Mission and Faculty Teaching Load 2010 – 2011 College of Pharmacy Research Day poster judge 2011 – 2015 Curricular Revision Steering Committee

2011 – 2013 Experiential Education Subcommittee 2014 – 2015 Phase III-Curriculum Development

2013 Riback Award Review Committee 2013 PhD Preliminary Committee (Candidate: Kibum Kim) 2013 – 2014 American Council for Pharmaceutical Education (ACPE) Self-Study

Committee 2014 Faculty Focus Group for the College of Pharmacy Teaching & Learning

Center 2016 Director of Assessment Search Committee 2017 – 2018 Senior Instructional Designer Search Committee 2018 – present Curricular Assessment Committee 2018 – present Head, Department of Pharmacy Practice Search Committee

MENTORING ACTIVITIES University of Illinois at Chicago College of Pharmacy


Curriculum Vitae

Page 32

2003 – 2016 Faculty Advisor Student/Faculty Advising Program

Class of 2006 Jessica Lattz, Norman Cheung Class of 2007 Malgorzata Bogun, Sarah Elkins, John Esterly, Nathan

Niemi, Adrienne Perotti Class of 2008 Annie Kannankeril, Jeff Hingtgen, Harn Shiue Class of 2009 Dominic Chan, Erin Goodwin, Brandon Pierce Class of 2010 Tatyana Lawrecki, April Sondag, Lara Ellinger Class of 2012 Prachi Shah, Stephen West Class of 2013 Dorothy Kus, Wynter Hollie Class of 2014 Cassidy McDonald, Marc McDowell, Pooja Shrivastav Class of 2015 Julie Bucek, Maggie Kaminska Class of 2016 Marina Koval

2003 – 2012 Faculty Advisor Pharmacy Practice/Post-Graduate Year 1 (PGY1) Residency Advisees: 2004 Karen King

2005 Emily Durr 2006 Adam Bursua 2007 Jonathan Dreslinski 2008 Elizabeth Greenhalgh 2009 Christopher Wilson 2010 Ashley Hall 2011 Sean Kane 2012 Yana Labinov

2006 – 2008 Thesis Advisor Department of Pharmacy Administration Pharmacoeconomics Fellowship Fellows: 2006 – 2009 Alexandra Perez

2007 – present Director Post Graduate Year 2 (PGY2) Residency in Cardiology Pharmacy American Society of Health-System Pharmacists (ASHP) Accredited, 2009 Trainees: 2008 – 2009 Elizabeth Greenhalgh

2010 – 2011 Adam Bress 2011 – 2012 Sarah Hanigan 2012 – 2013 Yana Labinov 2013 – 2014 Dejan Landup 2014 – 2015 Nicole (Gasbarro) Zimbardi 2015 – 2016 Alexandra Goncharenko 2016 – 2017 Stephanie (Dwyer) Kaluzna 2017 – 2018 Jaclynne (Metayer) Gowen

2013 – present Faculty Mentor Department of Pharmacy Practice Faculty Mentoring Program Mentees: 2013 – present Ryan Rodriguez 2013 – present Alan Gross

2013 PhD Preliminary Exam Committee Member Department of Pharmacy Systems, Outcomes, & Policy

PhD Student: Kibum Kim

2014 – present PhD Dissertation Committee Member Department of Pharmacy Systems, Outcomes, & Policy

PhD Student: 2014 – 2016 Kibum Kim 2015 – present Hari Patel

2017 – present Pharmacy Learning, Advising, Mentoring, and Engagement for Students (PhLAMES)


Curriculum Vitae

Page 33

Students: 2017 – present James Cheng 2017 – present Nita Mukand 2017 – present Jeffrey Allen 2017 – 2018 Egle Dauksaite

2018 – present Noah Burlison 2018 – present Jason Chung

Illinois Council of Health-System Pharmacists (ICHP)

2004 – 2012 Faculty Mentor Student Mentoring Program Students: 2004 Elizabeth Greenhalgh

2005 Denise Cheung 2006 Carolyn Szigethy 2008 Sam Lin 2010 Stephanie Leung 2012 Loriel Solodokin

American Society of Health-System Pharmacistts (ASHP) Research and Education Foundation

2006 – 2009 Main Co-Preceptor Antithrombotic Pharmacotherapy Traineeship

Selected as one of eight training sites nationally Trainees: 2007 Shahnaz Milani

Dusica Szczybura 2008 Bernard Roberts

Paris Abrams 2009 Crystal Hoffmann

Jennifer Costello

American College of Clinical Pharmacy (ACCP)

2007 – 2009 Director American College of Clinical Pharmacy (ACCP) Heart Failure Traineeship Selected as one of six sites nationally Trainees: 2008 Kristen Charlson

Andrea Dooley Debra Carabello

2009 Christie Schumacher Katherine Carey

Hannah Han Hsien Hwei

2014 – present Member Cardiology Practice & Research Network (PRN) Mentorship Committee Mentees: 2016 Carolyn Hempel (SUNY-Buffalo,

Novartis) 2017 – present Miranda Aimon (University of South

Florida) 2017 Gelson Taube (St. Joseph Hospital)

2018 – present Joseph H. Schafer (Augusta University Medical Center)

2018 – present Erik Kellison (Franciscan Heart and Vascular Associates at St. Joseph Medical Pavillion)

Heart Failure Society of America (HFSA)

2016 – 2017 HFSA Annual Speed Mentoring Session Mentor 2017 – present HFSA Faculty Mentor Mentees: 2017 – present Yekaterina Opsha (Rutgers University)


Curriculum Vitae

Page 34

TEACHING EXPERIENCE University of Malta International Collaborative Programmes Doctorate in Pharmacy

2018 – present Pharmacotherapeutics II (PHR5617)

University of Illinois at Chicago College of Pharmacy; University of Illinois Medical Center at Chicago

Experiential Introductory & Advanced Pharmacy Practice Experiences (IPPE & APPE) 1996 – 1997, Medicine/Advanced Medicine Clerkship Preceptor 2012 – 2017 PMPR 387, PMPR 353, PMPR 395 (APPE) 1999 – 2009 Advanced Medicine Critical Care/Cardiology Preceptor PMPR 389, PMPR 664 (1999 – 2004) (APPE) 2000 – 2017 Experiential II Facilitator: PHAR 352 (IPPE) 2000 – 2017 Experiential III Facilitator: PHAR 353 (IPPE) 2000 – 2017 Experiential IV Facilitator: PHAR 354 (IPPE) 2007 – 2017 Experiential I Facilitator: PHAR 342 (IPPE) 2008 – 2017 Medicine Clerkship Preceptor: PHAR 374 (APPE) 2008 – 2017 Experiential V Preceptor: PHAR 357 (IPPE) 2017 – present Medicine/Advanced Medicine Clerkship Co-Preceptor: PMPR 387, PHAR 374 2018 – present PHAR 515: Introductory Pharmacy Practice Experience Co-Preceptor Residency Preceptor (Critical Care/Cardiology/Cardiothoracic Surgery) 1999 – present PGY1 Pharmacy Practice Residency Preceptor (required, electives) 2000 – present PGY2 Critical Care Residency Preceptor (required) 2007 – 2017 PGY2 Emergency Medicine Residency Preceptor (elective) 2007 – 2017 PGY2 Organ Transplant Residency Preceptor (elective) 2008 – present PGY2 Cardiology Residency Preceptor (required, electives)

Visiting Scholars Preceptor 1999 Kyoshi Mihara (Japan) 2000 Margaret Lin (Taiwan), Emma Boxall (England), Wen-Ling Fu (Taiwan) 2001 M. S. Ganachari (India) 2003 Cheryl Kmet (Canada) 2006 Christine Teng (Singapore) 2009 Lilly Tung (Taiwan), Claire Hsin (Taiwan) 2011 Hou Meng Chong (Singapore) 2012 Ryuichi Ogawa (Japan) 2013 Susanna Bordignon (Italy) 2018 Wipharak Bunmark (Thailand)

Didactic

University of Illinois at Chicago College of Pharmacy

1997 – 1998 Acute Medical Emergencies I: PMPR 366 1998 Ambulatory Care Elective: PMPR 371 1998 – 2000 Careers in Pharmacy: PMPR 375 1998 – 2004 Physical Assessment: PHAR 656 1999 – 2001 Principles of Drug Action and Therapeutics V: PHAR 405 1999 – 2000 Pathophysiology: PHYB 301 2000 – 2008 Critical Care I: PMPR 430 2001 – 2003 Pharmacotherapeutics 651: PHAR 651 2001 – 2016 Principles of Drug Action and Therapeutics II: PHAR 402 2003 – 2007 Experiential IV: PHAR 354 (formerly part of PHAR 353) 2003 – 2008 Applied Pharmacokinetics: PMPR 440 (formerly PMPR 385/340) (Course Coordinator/Course Developer)


Curriculum Vitae

Page 35

2004 – 2005 Undergraduate Research in Pharmacy Practice: PMPR 380 Topic: Development and Verification of a Modern Dosing Nomogram for Digoxin (Student: Melissa Fitch) 2005 – 2016 Basic Pharmacokinetics: PHAR 400 2005 – 2006 Special Projects in Pharmacy Practice: PMPR 390 Topic: Development and Verification of a Modern Dosing Nomogram for Digoxin (Student: Melissa Fitch) 2006 Special Projects in Pharmacy Practice: PMPR 390 Topic: Medication Use Evaluation of IV Heparin Dosing in Hospitalized 2007 Undergraduate Research in Pharmacy Practice: PMPR 380 Topic: Medication Use Evaluation of IV Heparin Dosing in Hospitalized Patients (Student: Harn Shiue) Patients (Student: Harn Shiue) 2007 – 2011 Seminar in Pharmacy Research: PMPR 355 2009 – 2010 Professional Development Seminar III: BPS/PMAD 383 2010 – 2011 Social and Behavioral Pharmacy: PHAR 344 2016 – present Integrated Physiology: PHAR 410 2016 – present Pharmacokinetics: PHAR 435 2017 – present Principles of Drug Action and Therapeutics V: PHAR 505 2018 – present College of Pharmacy Colloquium: BPS 425 2019 – present Principles of Drug Action and Therapeutics X: PHAR 510

University of Illinois at Chicago College of Medicine

2013 Medical Pharmacology: PRCL 628

University of Illinois at Chicago Honors College

2013 Honors Seminar Course: HON 201 (undergraduates in the Honors College)

OTHER PROFESSIONAL ACTIVITIES Abstract Reviewer

2017 American College of Cardiology

Grant Reviewer 2015 California Northstate University College of Pharmacy Seed Grant 2015 Heart Failure Society of America (HFSA) Clinical Research Grants 2016 Heart Failure Society of American (HFSA)/Emergency Medicine Foundation

(EMF) Research Grants 2016 Heart Failure Society of America (HFSA) Research Fellowship Grants (St. Jude

Medical Research) 2016 American College of Clinical Pharmacy (ACCP) Research Institute Futures

Grants 2017 Heart Failure Society of America (HFSA) Mini Nursing Research Grants Promotion and Tenure External Reviewer

2009 University of Southern California Associate Professor of Clinical Pharmacy promotion candidate

2010 Western University of Health Sciences Associate Professor of Clinical Pharmacy promotion candidate

2011, 2012 Purdue University Clinical Associate Professor of Pharmacy Practice promotion candidates

2012 Wayne State University Associate Professor (Clinical) of Pharmacy Practice promotion candidate


Curriculum Vitae

Page 36

2014 University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Assistant Professor reappointment candidate (midpoint assessment for promotion)

2014 University of Missouri Kansas City Clinical Associate Professor of Pharmacy Practice and Administration promotion candidate

2016 University of Tennessee College of Pharmacy Professor (non-tenured) candidate 2017 University of North Carolina Eshelman School of Pharmacy Clinical Professor

candidate 2018 Rosalind Franklin University of Medicine and Science Associate Professor

(Clinical Educator track) candidate Editorial Activities

2014 – 2016 Consulting editor, J Pharm Pract 2016;29(1): Cardiology Pharmacotherapy Special issue

2017 – present Editorial board member, Journal of the American College of Clinical Pharmacy Reviewer/Referee

1997 – 2017 Annals of Pharmacotherapy 1997 – 1998 Clinical Therapeutics 1998 – present Pharmacotherapy 1997 – 1999 University Health-System Consortium Drug Monograph 2000 Expert Opinion on Pharmacotherapy 2000 Medical Education Resources 2002 – 2004 RxPress 2003 Premier Purchasing Partners 2004 KeePosted 2005 The Medical Letter 2005 Archives of Internal Medicine 2006 American Society of Health-System Pharmacists 2008 ProCE 2009 American Journal of Cardiology 2009 Pharmacy Practice 2009 – 2010 Pharmacotherapy Self-Assessment Program (PSAP) VII Urgent

Care/Critical Care 2009 – 2010 Current Medical Research and Opinion 2010 – 2016 Journal of Cardiac Failure 2013 Journal of Cardiothoracic Surgery 2013 – 2014 Ambulatory Care Self-Assessment Program (ACSAP) Cardiology Care 2014 Thrombosis Journal 2016 Hospital Pharmacists Letter 2017 Pharmacists Letter 2017 – present Circulation: Heart Failure 2018 – present Journal of the American College of Clinical Pharmacy

National Advisory Boards

2001 – 2002 Novation MUE Program Glycoprotein IIb/IIIa Inhibitor Expert Panel 2001 Cerner Corporation Clinical Notification Expert Panel 2003 Alza Pharmaceuticals Advisory Board 2005 Scios, Inc. Regional Pharmacy Advisory Board 2005 Scios, Inc. National Pharmacy Advisory Board 2005 Focus Group on IHN (Novation, University Health Consortium, VHA)

Perspectives on the Treatment of Acute Decompensated Heart Failure 2006 Ranexa Advisory Board (CV Therapeutics) 2006 NitroMed Clinical Pharmacy Advisory Board


Curriculum Vitae

Page 37

2007 Natrecor® Advisory Panel (Scios, Inc.) 2008 Multaq® Quality Improvement Advisory Board. (Sanofi-Aventis) 2008 Pharmacy/Integrated Health Network (IHN) Advisory Board for Angiomax® (The

Medicines Company) 2009 Merck & Co. U. S. Heart Failure Expert Input Forum 2009 ARCA biopharma, Inc. Gencaro® Advisory Board 2010 – 2011 Medscape Drug Reference Advisor 2010 American Pharmacists Association (Special Report: “Updates in the

Management of Chronic Stable Angina”) 2010 Merck & Co. Cardiovascular Outcomes Research Advisory Panel 2011 F. Hoffmann-La Roche Ltd Cardiovascular Advisory Board 2013 Novartis Pharmaceuticals Corp. Hospital Pharmacy Perspectives on Acute Heart

Failure Advisory Board 2014 Novartis Pharmaceuticals Corp. Chronic Heart Failure Commercial Advisory

Board 2014 Amgen Hospital Pharmacy Cardiovascular Advisory Board 2014 Novartis Pharmaceuticals Corp. Acute Heart Failure Hospital Pharmacy Decision

Maker Early Experience Program Advisory Board 2015 Otsuka America Pharmaceutical, Inc. SCORE Tool Advisory Board National Speaker Bureaus

1998 – 2004 Integrilin® Speaker Bureau (Shering-Plough, Key Pharmaceuticals, Millenium Pharmaceuticals, COR Therapeutics)

2000 – 2002 Cordarone® IV Educator 2000 – 2001 Tikosyn™ Medical Educator (Pfizer, Inc./Current Medical Directions, Inc.) 2000 – 2001 Bristol-Myers-Squibb Speaker Bureau (Pravachol®, Plavix®) 2004 – 2006 University Pharmacotherapy Associates, LLC Acute Decompensated Heart

Failure speaker program 2005 – 2007 Natrecor® Speaker Bureau (Scios, Inc.) 2007 – 2010 STRIVE™ Critical Pathways CME/CE Workshop (Bristol-Myers-Squibb, Sanofi

Pharmaceuticals, Sanofi-Aventis US, Inc.) 2007 – 2008 University Pharmacotherapy Associates, LLC Acute Coronary Syndrome speaker

program CONSULTING RELATIONSHIPS 2002 – 2004 Abbott Laboratories. 2002 – 2003 Baxter Healthcare Corp. 2006 – 2007 Heyl, Royster, Voelker, & Allen 2006 Rakoczy Molino Mazzochi Siwik LLP. 2012 Clarus Acuity Group, Inc. 2012 Cassiday Schade LLP 2013 Edwards Wildman Palmer LLP

COMMUNITY & PROFESSIONAL SERVICE Professional Interviews

2000 Interviewed for Cover Story on “The pharmacist’s role on anticoagulation team expanding as anticoagulant usage increases” for Hospital Pharmacist Report. Vecchione A. Anticoagulation: New Therapeutic Challenges: R.Ph.s becoming vital members of health-care team as anticoagulant use increases. Hospital Pharmacist Report 2000;14:31-2.


Curriculum Vitae

Page 38

2000 Television interview on WBBM-TV (CBS) Channel 2 News at 10 regarding new FDA warning on the serious cardiovascular complications associated with Propulsid (cisapride). “On Call with Dr. Michael Breen, MD”. Segment aired January 24, 2000.

2003 Interviewed for story appearing in the University of Illinois at Chicago donor recognition newsletter. McKeough K. “Pharmacy Fraternities Endow Scholarship Funds: Gifts from Kappa Psi, Phi Delta Chi Alumni Help Foster Student Leadership”. Investing in UIC; December, 2003.

2003 Interviewed for story appearing in Pharmacy Practice News. Hurley D. “PDAs Can Be Pharmacist’s Best Friend When It Comes to Proper Antibiotic Prescribing”. Pharmacy Practice News 2004;31. November, 2003.

2007 Interviewed for story entitled “Multiple changes spawn new UA/NSTEMI guidelines” appearing in Drug Topics; September 17, 2007.

2007 Interviewed for story on “5 drug interactions to keep on your radar” appearing in the family health issue of the Chicago Tribune’s Sunday magazine. Chen D. “Take Five”. Chicago Tribune Magazine; March 4, 2007.

2010 Interviewed for story entitled “New antiplatelet agents enter a market dominated by clopidogrel: Prasugrel, ticagrelor, and more to come.” appearing in Pharmacy Today. October, 2010. http://apha.imirus.com/Mpowered/imirus.jsp?volume=pt16&issue=10&page=38

2012 Interviewed for story entitled “Is fibrate-statin ban a bad idea?” appearing in Pharmacy Practice News. December, 2012;39.

2013 Interviewed for story entitled “Fibrate-statin changes mandate new safety protocols?” appearing in Pharmacy Practice News. January, 2013;40.

2014 Interviewed for story entitled “Pharmacists part of interventions in readmission programs for patients with heart failure, AHRQ says.” appearing in Pharmacy Today 2014;20(7).

2017 Interviewed for story entitled “CardioMEMS PA-pressure sensor: prowess, cautions in HF management” appearing on Medscape. September 19, 2017.

2018 Interviewed for story entitled “Despite increased mortality, DOAC safety data offer reassurance” appearing in Pharmacy Today 2018;24(9):4.

American Pharmacists Association

2018 Panelist, American Pharmacists Association (APhA) University of Illinois at Chicago (UIC) Chapter Heart Operation

American Heart Association

2004 – 2012 Participant, American Heart Association Heart Walk c/o University of Illinois Medical Center at Chicago. 2004 – 2012.

2010 Team Captain (Inpatient Pharmacy), American Heart Association Heart Walk c/o University of Illinois Medical Center at Chicago. 2010.

St. Alphonsus/St. Patrick School

2014 – 2015 Assistant Coach, Boys Basketball. Lemont Park District Lepercauns. Lemont, IL.

2015 – 2017 Assistant Coach, Boys Basketball, 5th-6th grades. St. Alphonsus/St. Patrick School. Lemont, IL.

2016 – 2018 Member, St. Alphonsus/St. Patrick School Celtic Fund Marketing Committee. Lemont, IL.


Curriculum Vitae

Page 39

2017 Member, St. Alphonsus/St. Patrick School Advisory Task Force Strategic Planning Subcommittee

2017 – 2018 Head Coach, Boys Basketball, 6th/7th grade. St. Alphonsus/St. Patrick School. Lemont, IL.

2018 – 2019 Head Coach, Boys Basketball, 5th/6th grade. St. Alphonsus/St. Patrick School. Lemont, IL

2018 – present Basketball Coordinator, St. Alphonsus/St. Patrick School Athletics Board. Lemont, IL.

2018 – present Head Coach, Boys Basketball, 7th/8th grade. St. Alphonsus/St. Patrick School. Lemont, IL

Miscellaneous

2004 Recognition by American Airlines for participating in the emergency medical care of a passenger in need of Advanced Cardiac Life Support during a flight from Chicago, Illinois to Reno, Nevada. September, 2004.

2004 Member, South Loop Dog Park Action Co-op (Dog P.A.C.). Involved in fundraising activities for the construction of a dog park at the south end of Grant Park in Chicago. 2004.

Documents

LICENSURE PROFESSIONAL EXPERIENCEweb-prod-2.pharm.uic.edu/webdav/rdidom1/pci/cv-Rob... · 2019-04-15 · Practice and Research Network outlining recommendations for training of cardiovascular